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Pancreatic cancer is the 4th leading cause of cancer related deaths in the US with a median 
survival of less than one year and an overall 5-year survival of less than 5%. Surgical resection is 
the curative option for patients with localized disease; however, less than 20% of patients have 
dissectible disease. Gemcitabine chemotherapy has been the standard care for nearly 20 years 
and it has little impact on overall survival rate. A recently developed gemcitabine-free regimen 
FOLFIRINOX showed a small improvement on the survival but it added significant toxicities. 
One of the reasons for such high mortality rate and poor treatment outcome is that pancreatic 
cancer is highly metastatic. The majority of the patients have locally or regionally spread and/or 
distant metastasis at the time of diagnosis. Moreover, these tumors are highly enriched with a 
cancer stem cell (CSC) population (~1%), which is highly resistant to chemotherapeutic drugs, 
and therefore escapes chemotherapy and promotes tumor recurrence.  
Recent evidence suggests that epithelial to mesenchymal transition (EMT) is associated with 
metastasis, generation of CSCs, and treatment resistance in solid tumors including pancreatic 
cancer. Therefore, compounds inhibiting EMT hold the potential to reverse drug-resistance or 
inhibit metastasis and CSCs, and therefore could provide better treatment outcome for patients 
with pancreatic cancer. The overall goal of this dissertation is to investigate novel EMT 
inhibitors for targeting pancreatic cancer metastasis and CSCs. This study resulted in the 
identification of several novel EMT inhibitors that have potential clinical significance for 
pancreatic cancer patients. 
 First, we demonstrated in preclinical models that treatment with pharmacological doses of 
ascorbate resulted in inhibition of EMT, metastasis and CSCs. High-dose intravenous ascorbate 
is now in clinical testing (Chapter 4).  
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Next, we investigated novel derivatives of the histone deacetylase (HDAC) inhibitors SAHA and 
MS-275, which are known EMT inhibitors. In an effort to increase efficacy and reduce toxicities 
of the HDAC inhibitors, we found that the novel synthetic compounds St-1 and St-3 potently 
inhibited pancreatic cancer cell proliferation and CSCs. St-1 has exhibited similar potency in 
HDAC inhibition compared to the parent compounds (SAHA and MS-275).  Surprisingly, St-3 
acted via totally different mechanisms from SAHA and MS-275. St-3 exhibited anti-tumor 
effects by blocking the interaction of human antigen R (HuR) with its target mRNAs (Chapter 5). 
 To date there is still a lack of highly efficient approach for discovery of CSC inhibitors. In an 
effort to solve the problem, we established and performed a high throughput screening (HTS) 
approach to identify EMT and CSC inhibitors. 1-(benzylsulfonyl) indoline (BSI) was found to be 
a novel EMT inhibitor. Several analogues of BSI were tested for their activities on EMT and 
CSC inhibition (Chapter 6). 
Overall this dissertation resulted in the identification of several novel EMT inhibitors, which can 
be tested further in preclinical or clinical studies for their anti-tumor efficacy. These pancreatic 
cancer EMT and CSC inhibitors each have their own merits. A pharmacological dose of 
ascorbate has an outstanding safety profile.  It inhibited pancreatic cancer EMT and CSCs.  In 
addition pharmacological dose of ascorbate affected the tumor microenvironment to inhibit 
cancer cell metastasis. In this way, ascorbate provides a unique opportunity to target both cancer 
cell growth as well as tumor microenvironment. Combining with its low toxicity profile, the 
clinical benefit of pharmacologic ascorbate in pancreatic cancer patients is worth investigating.  
The compound St-1 showed better potency in inhibiting pancreatic cancer cell growth than 
currently used HDACs, showing the potential of having a larger therapeutic index and better 
efficacy than its parent compounds.  The compound St-3 is a novel HuR inhibitor and provided a 
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novel therapeutic target for pancreatic cancer treatment. The compound BSI is structurally 
different from other EMT inhibitors, and thus could become a new class of EMT inhibitors. The 
work in this dissertation set a basis for advancing these EMT inhibitors towards drug 
development for pancreatic cancer treatment. It has opened the door for further preclinical, 
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1.1. Pancreatic cancer 
Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, and it is 
expected to become the second-leading cause of cancer-related death by 2030. The American 
Cancer Society estimated that 48,960 (men=24,840, women=24,120) people will be diagnosed 
with pancreatic cancer in 2015 and that 40,560 (men=20,710, women=19,850) will die from the 
disease. Most of the pancreatic cancer cases (96%) are cancers of the exocrine pancreas. 
Currently, there are no early detection tests and most patients with localized disease have no 
recognizable symptoms. As a result, more than half of the patients with this disease are 
diagnosed at a stage where metastases have developed, for whom the overall 5-year survival is 
only 2% (8, 9).  
A spectrum of distinct pancreatic malignancies have been identified that resemble normal 
cellular counterparts, such as pancreatic ductal adenocarcinoma (PDAC), acinar cell carcinoma, 
pancreato blastoma, solid pseudopapillary neoplasm, serous cystadenoma, and pancreatic 
endocrine tumors. Among these, PDAC, whose name is derived from its  histological 
resemblance to ductal cells, is the most common pancreatic neoplasm and accounts for >85% of 
pancreatic  cancer cases (4). 
1.1. 1. Evolution of PDAC and its morphological characteristics 
PDAC makes up over 90% of all pancreatic neoplasms (10). The majority of PDACs arises in 
the head region of the pancreas and exhibits a glandular pattern resembling ductal epithelial cells 
with varying degree of differentiation. Clinical and histological studies identified three different 
types of precursor lesions: pancreatic intra epithelial neoplasia (PanIN), mucinous cystic 
neoplasm (MCN), and intraductal papillary mucinous neoplasms (IPMN) that led to PDAC (Fig. 
1). Of these, PanIN is the most extensively studied precursor lesion. PanIN is graded into stages 
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1 to 3. PanIN 1 is characterized by columnar 
mucinous epithelium with slight nuclear 
atypia. PanIN 2 and 3 are characterized by 
more disorganized structural architecture 
and nuclear atypia. MCN and IPMN are less 
common precursor lesions. MCNs are large 
mucin producing columnar epithelial cystic 
lesions supported by ovarian type stroma 
usually found in the body and tail of 
the pancreas. IPMN arises in the main 
pancreatic duct or its major branches 
and resembles PanIN at cellular levels 
but grows into  large cystic structures 
(11). 
 
1.1.2. Molecular biology of 
pancreatic cancer 
Comprehensive genetic analysis 
revealed that pancreatic cancer contains an average of 63 genetic alterations. All these mutations 
are grouped into 12 different core signaling pathways that were altered in 67-100% of the 
tumors. The most commonly observed signature genetic lesions in pancreatic cancer are kirsten 
rat sarcoma viral oncogene homolog (K-Ras), P16/ cyclin-dependent kinase inhibitor 2A 
(CDKN2A), tumor protein P53 (P53), breast cancer 2 early onset (BRCA2) and SMAD family 
Figure 1- Pancreatic precursor lesions and 
genetic events involved in pancreatic 
adenocarcinoma progression (4). PanIN, IPMN, 
MCN represents three known precursor lesions of 
PDAC. PanINs classified into three grades: PanIN-
1, 2 and 3 which then eventually develop to 
PDAC. Development of PDAC from IPMN and 
MCN shown on right side of the picture. Early 
genetic alterations (K-Ras mutations, P16 loss) 
and late genetic alterations (P53 loss, SMAD4 
loss,) that occur in adenocarcinomas also occur in 
PanIN and to lesser extent in IPMNs and MCNs 
represented in the middle of the picture. Asterisks 
indicate events (telomere shortening, BRCA2 




member 4 (SMAD4)/ deleted in pancreatic carcinoma 4 (DPC4) (12). In patients, K-Ras 
mutations are often considered as an initiating event occurring in adult cells, soon followed by 
mutation to P16 and later P53 and SMAD4 loss. 
The K-Ras oncogene.  K-Ras is activated by point mutations in more than 90% of the pancreatic 
cancer patients and represents the most frequent and the earliest genetic alteration, being found 
in low-grade PanIN lesions (12, 13). Continuous K-Ras signaling is required for pancreatic 
cancer cells for sustained proliferation and survival (14). Ras proteins belong to the small G 
protein superfamily, and their activity is regulated by guanine nucleotides such as GTP and GDP. 
Ras downstream signaling pathways are activated if Ras binds to GTP, and are inactivated if Ras 
binds to GDP. Active and inactive states of Ras signaling are regulated by guanine nucleotide 
exchange factors (GEFs) and GTPase activating proteins (GAPs). GEFs aid in exchange of GDP 
for GTP. GAPs activate intrinsic GTPase activity of Ras protein to hydrolyze GTP into GDP 
(15). Any mutations that inactivate the GTPase constitutively activate Ras signaling and 
downstream effector pathways. For example, a single point mutation of codons G12 or G13 in K-
Ras abolishes GAP induced GTP hydrolysis, thereby making K-Ras a constitutively active form. 
Therefore, a pancreatic specific mutation of codons G12D or G12V is sufficient to develop 
acinar to ductal metaplasia and PanIN, which then progress to PDAC. PDAC development can 
be accelerated in the K-Ras mutant mouse by introducing additional mutations in tumor 
suppressor genes such as p53, SMAD4, and P16/CDKN2A, all of which occur frequently in 
precursor lesions as they progress to invasive PDAC (16). 
K-Ras signaling engages various downstream effectors. In PDAC, K-Ras predominantly signals 
through canonical Raf/mitogen activated protein kinase (MAPK)/ extracellular signal-regulated 
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kinase (Erk), phosphoinositide 3-kinases (PI3Ks)/ 3-phosphoinositide dependent protein kinase-1 
(PDK-1)/Akt, Ral guanine nucleotide exchange factors (RalGEFs), and phospholipase Cε (15).  
 Mutations or alternations in these downstream pathways complicate K-RAS driven PDAC. For 
example,  expression of PIK3CA H1047R (codes for p110α H1047R), a constitutively active 
oncogenic class 1A PI3K in Ptf1a positive cells, induced acinar to ductal metaplasia and 
premalignant pancreatic intraepithelial neoplasia, recapitulating K-Ras G12D driven PDAC.  
Elimination of PDK-1, blocked K-RasG12D driven PDAC (17). RalGEF induces oncogenic 
activity by activating its substrate RalA (18). RalA is required for tumor initiation, whereas the 
other RalGEF substrate, RalB, is required for metastasis in Ras-driven pancreatic cancers (19).  
Tumor suppressor genes (P16/CDKN2A, TP53, and SMAD4/DPC4). P16/CDKN2A is the most 
commonly inactivated tumor suppressor gene in pancreatic cancer. P16/CDKN2A inhibits 
CDK4/6 mediated phosphorylation of retinoblastoma (RB) protein, thereby blocking entry into 
the S phase of the cell cycle. Inactivation of P16/CDKN2A occurs by different mechanisms, 
including homozygous deletions, loss of heterozygosity and epigenetic silencing by promoter 
methylation (20). P16/CDKN2A cooperated with K-Ras in the development of PDAC (21). 
Mutations in K-Ras exert selective pressure for subsequent mutation in P16/CDKN2A, which 
cooperate to lead to the development of PDAC. In precursor lesions, oncogenic K-Ras 
expression co-exists with P16/CDKN2A and other markers of senescence.  In PDAC, expression 
of P16/CDKN2A and senescence markers are missing (22).  
 P53 is inactivated in 50-75% of PDAC cases and the inactivation occurs via intragenic 
mutations combined with loss of the second allele (23). P53 mutations observed in the late 
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PanIN stage usually lead to loss of p53 function, and subsequently   provides growth and 
survival advantage for the cells which harbor chromosomal aberrations (24). 
SMAD4 is a key signal transducer of TGF-β signaling pathway. SMAD4 is inactivated in 
approximately 55% of pancreatic cancer cases either by homozygous deletions or by intergenic 
mutations and loss of the second allele (25). Loss of SMAD4 provides growth advantage for 
pancreatic cancer cells by abrogating the growth inhibitory signals mediated by TGF-β (26) in  
late PanIN stage (PanIN-3) (27).  Patients undergoing surgical resection of their pancreatic 
adenocarcinoma survived longer if their cancer expressed SMAD4 (28).   
Growth factor receptor signaling in PDAC. PDACs overexpress multiple mitogenic growth 
factors and their ligands. These include: the epidermal growth factor (EGF) and its receptor 
(EGFR), and multiple ligands that bind to EGFR;  fibroblast growth factor (FGF) and its receptor 
(FGFR) and ligands; insulin-like growth factor (IGF) and its receptor (IGFR); platelet derived 
growth factor; and vascular endothelial growth factor (VEGF) (29, 30).  
EGFR is a transmembrane receptor tyrosine kinase, activated upon binding of its ligands, EGF 
and transforming growth factor-α (TGF-α). Upon activation EGFR stimulates phospholipase C 
gamma (PLC-γ). EGFR overexpression was detected in up to 90% of pancreatic tumors (31), and 
plays an important role in liver metastasis and recurrence of human pancreatic cancer (32). 
EGFR inhibitors decrease PDAC cell growth and tumorigenesis in vitro (33) and inhibited 
growth of orthotopic tumors when combined with chemotherapy (34). However, EGFR targeting 
agents in combination with gemcitabine did not provide many beneficial effects to pancreatic 
cancer patients in the clinic (31). Resistance to EGFR inhibitors may be due to activation of 
alternative receptor tyrosine kinase pathways (e.g. c-Met and IGF-1R) which bypass or evade 
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inhibition of EGFR signaling. Constitutive activation of downstream mediators of EGFR 
signaling pathway such as PTEN, K-Ras also provide resistance to EGFR targeted therapies (31, 
35). 
The IGFs and their receptors have been acknowledged as important players in a variety of 
cancers (36) by  regulating  cell survival, invasion, and angiogenesis (37). In PDAC patients, 
elevated expression of IGF-1 and its receptor IGF1R are associated with higher tumor grade and 
poor survival (38-41).  In vitro experiments showed that exogenously added IGF-1 enhanced the 
growth of human pancreatic cancer cells and this effect was inhibited by IGF-1 neutralizing 
antibody (38).  However, clinical trials performed with IGF1R blocking antibodies were largely 
disappointing (42). In 2012, Amgen announced termination of a large phase 3 clinical trial in 
patients with metastatic PDAC treated with the IGF1R blocking antibody ganitumab (AMG 479) 
and gemcitabine. The ganitumab and gemcitabine combination failed to improve overall survival 
compared to gemcitabine alone 
(http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1723925). 
FGFR is a transmembrane protein that triggers phosphorylation of an adaptor protein FGFR 
substrate 2 (FRS2) upon binding of FGF. Phosphorylated FRS2 then recruits and activates 
elements of Ras/MAPK and PI3K/Akt pathways. Overexpression of ligands (FGF1-7) and 
receptors (FGFR-1 and FGFR-2) contributed to mitogenesis and angiogenesis in a subset of 
pancreatic cancers (43-45).  Inhibition of FGFR signaling using shRNA or dovitinib (a tyrosine-
kinase inhibitor) achieved significant anti-cancer effects in preclinical pancreatic cancer models 
(46). Dovitinib is currently at clinical development for patients with metastatic pancreatic cancer, 
biliary cancers and pancreatic neuroendocrine tumors (https://clinicaltrials.gov identifier: 
NCT01497392, NCT01888965, NCT02108782).  
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Vascular endothelial growth factor (VEGF) is an angiogenic polypeptide.  It promotes 
endothelial cell proliferation and survival by binding to its receptors VEGFR-1 and VEGFR-2 
(47). Though PDAC is not a highly vascularized tumor, foci of endothelial cell proliferation are 
often observed in this malignancy.  Patient tumor samples showed increased expression of VEGF 
mRNA and its expression correlated with high micro vessel density and disease progression (48, 
49). TNP-40, an analog of fumagillin, which is an anti-angiogenic agent, decreased tumor 
growth and metastasis of pancreatic cancer cell lines in subcutaneous mice model system (50). 
Adenoviral vectors carrying the VEGFR tyrosine kinase inhibitor PTK 787 also inhibited the 
growth and metastasis of pancreatic cancer in preclinical models (51). Phase 1/2 studies of 
PTK787 plus gemcitabine (https://clinicaltrials.gov identifier: NCT00185588) in advanced 
pancreatic cancer showed promising results, and phase 2 studies are on-going 
(https://clinicaltrials.gov identifier: NCT00226005).  
As our understanding has grown tremendously in oncogenic K-Ras, tumor suppressors, growth 
factors and their receptors in pancreatic cancer initiation and progression, approaches are being 
tested to target oncogenic K-Ras and growth factors. However, it remains challenging to improve 
treatment for this disease with complicated genetic and molecular alternations.  It also remains 
challenging for researchers to further understand the molecular genetics of tumor suppressor 
proteins in pancreatic cancer, to restore their normal function by gene therapy, or to develop 
small-molecule inhibitors that reactivate tumor suppressor function (52). Novel approaches to 
target tumor suppressor genes need to be discovered and tested with open mind. 
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1.2. Epithelial to mesenchymal transition (EMT)  
1.2.1. Basics of EMT  
Most of the pancreatic cancer-related deaths are due to metastatic disease. Recent studies in 
animal models revealed that pancreatic cancer cells undergo dissemination from the primary 
tumor and get metastasized to liver even before frank malignancy was detected at the primary 
site of origin. The developmental program of epithelial to mesenchymal transition (EMT) is of 
virtual importance for this rapid tumor progression (53).  
EMT is a multistage trans-differentiation process which allows highly polarized epithelial cells 
to undergo multiple biochemical changes to attain mesenchymal phenotype (Fig.2.1). Epithelial 
cells display apical-basolateral polarity and are organized in cell layers with strong cell-cell 
adhesion. Mesenchymal cells are spindle shaped, exhibit anterio-posterior polarity and strong 
migratory potential. During EMT progression, epithelial cells lose their epithelial markers (such 
as E-cadherin, occludin, claudin, and laminin 1) and gain mesenchymal markers (such as N-
cadherin, vimentin, and fibronectin) (6).  
EMT is classified into three major types based on the context in which it occurs. Type 1 EMT is 
associated with implantation, embryo formation, and organ development. Mesenchymal cells 
generated by Type 1 EMT have potential to undergo mesenchymal to epithelial transition (MET) 
and generate secondary epithelia. Type 2 EMT is associated with inflammation processes and 
plays a major role in wound healing, tissue regeneration, and organ fibrosis. Type 3 EMT occurs 
in carcinoma cells (Fig. 2.2) and is considered important at several different stages 
(dissemination, invasion, intravasation and extravasation) during tumor progression (6, 54). 
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Figure 2.2- Type-3 EMT leads to cancer cell invasion and metastasis (6). 
Conversion of normal epithelium to invasive carcinoma is a multi-stage process. 
First, primary epithelial cancer cells lose their polarity and detach from the 
basement membrane. The next step involves basement membrane breakage, cancer 
cell EMT followed by intravasation into blood vessels. Cancer cells survive in 
circulation and exit the blood stream to form micro and macro metastasis, which 


















Figure 2.1- Characteristics of EMT involve a functional transition of polarized 
epithelial cells into mesenchymal cells (6).  Epithelial cells are highly polarized in nature 
with apical and basolateral polarity. E-cadherin, claudins, occludins, desmoplakin, type IV 
collagen, and laminin-1 are markers of epithelial cells. Mesenchymal cells are spindle 
shaped and are highly motile in nature. N-cadherin, α5 β1 integrin, αvb6 integrin, 
vimentin, type-1 collagen, laminin-5 and fibronectin are the markers of mesenchymal 
cells.  During EMT progression, epithelial cells loose epithelial markers and gain 
mesenchymal markers. Cells that express markers of epithelial and mesenchymal cells 




Metastatic tumor cells have the potential to migrate through the bloodstream and in some cases, 
form secondary tumors at other sites through MET (55, 56). During type 3 EMT, some cells 
retain epithelial traits while acquiring mesenchymal features and other cells shed most epithelial 
features and become fully mesenchymal (55, 57). 
 
 












Figure 3- EMT involves an intricate interplay of multiple signaling pathways 
(5).  Activation of different signaling pathways such as Wnt, growth factors 
(GF), TGF-β, Notch, HIF1α and TNF-α induces expression of transcription 




A complex network of signaling pathways governs EMT in tumor progression. Both soluble 
factors (TGF-β family members, FGF, HGF, Wnt, TNFα, Notch, HIF1-α), as well as non-soluble 
components of the extracellular matrix (collagen and hyaluronic acid) guide epithelial 
mesenchymal transition during cancer progression (58, 59). These signaling events primarily 
induce EMT by inducing transcription factors such as Snail family of zinc finger transcription 
factors (Snail 1, Snail 2), zinc-finger-enhancer binding protein (Zeb-1 and 2) and basic helix loop 
helix (bHLH) family members (E12, E-47, and Twist) (Fig.3). A common feature of these 
transcription factors is repression of the CDH1 gene that encodes E-cadherin (16). Reduced E-
cadherin expression is a key initial step in the trans-differentiation of epithelial to a mesenchymal 
phenotype, invasion and metastasis.   
TGF-β signaling pathway in EMT. TGF-β is one of the most important EMT-inducing factors 
in a diverse range of tumor cells, including pancreatic cancer cells (60). The canonical TGF-β 
signaling proceeds as follows. Binding of TGF-β to a TGF-β type II receptor leads to the trans-
activation of type I receptor (TβR I). TβR I is a serine/threonine kinase that subsequently 
phosphorylates SMAD2 and 3, which then forms a complex with SMAD4 and translocates to the 
nucleus to regulate the transcription of target genes (58). Transcriptional activation of Twist, 
Snail, Slug, and Zeb-1 has been shown to be critical for TGF-β mediated EMT induction in a 
majority of cancers (61).  
In pancreatic cancer with SMAD4 inactivation, TGF-β might induce EMT through the non-
canonical pathway (i.e. SMAD-independent pathway) (58), which involves ERK/MAPK, PI3K, 
p38, JNK, RhoA, and other signaling pathways (62). In some pancreatic cancer cell lines such as 
Colo-357, depletion of SMAD4 using RNAi did not disrupt EMT responses in these cells (63). 
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In other pancreatic cancer cell lines, TGF-β induced EMT was reversed by the MEK-1 inhibitor 
PD98059 (60).   
Wnt/β-catenin signaling pathway. The canonical Wnt/β-catenin signaling pathway proceeds in 
the following manner. In the absence of Wnt ligand, β-catenin is kept low by a destruction 
complex which consists of axin, adenomatous polyposis coli, glycogen synthase kinase-3β 
(GSK-3β) and casein kinase (CK-1). CK-1 first phosphorylates β-catenin at Ser45, which primes 
β-catenin. Primed β-catenin is phosphorylated by GSK-3β, at Thr41, Ser33 and Ser37, ultimately 
leading to ubiquitination and proteosomal degradation by β-Trcp. This persistent removal of β-
catenin prevents β-catenin nuclear accumulation. Therefore, Wnt target genes are repressed by 
DNA bound T cell factor (TCF)/lymphoid enhancer factor (LEF) and HDAC. Wnt ligand 
binding to Frizzled and LRP5/6 receptors complex leads to phosphorylation of LRP5/6. Phospho 
LRP5/6 binds axin leading to dissociation of the destruction complex and inactivation of GSK-
3β, thereby stabilizing cytosolic β-catenin and promoting its nuclear localization. In the nucleus 
β-catenin forms a complex with TCF/LFE and activates expression of Wnt target genes such as 
cyclin D1 and c-MYC (64).   
The Wnt/β-catenin pathway is associated with EMT induction (65). GSK-3β phosphorylates 
Snail, and promotes Snail proteosomal degradation. Wnt suppresses the activity of GSK-3β and 
stabilizes the protein levels of Snail, and therefore induces EMT and stem-like properties in 
cancer cells (66). Oncogenic K-Ras  activate  the Wnt/β-catenin signaling pathway, which in turn 
up-regulates  EMT stimulators such as Snail and Zeb-1 (67). Inhibition of the Wnt/β-catenin 
signaling pathway blocks EMT.  Restoration of the Wnt inhibitory factor 1 (WIF-1) expression  
resulted in increased expression of epithelial markers and decreased expression of mesenchymal 
markers, by  decreased expression of Slug and Twist (68). Small hairpin RNA knockdown of  β-
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catenin resulted in elevated expression of E-cadherin, decreased expression of the mesenchymal 
markers vimentin, N-cadherin, MMP-2, indicating the reversal of EMT (69). 
Notch signaling pathway. The Notch-signaling pathway plays an important role in the 
development of organs, tissue proliferation, differentiation and apoptosis (70). To date, four 
Notch receptors (Notch1-4) and five Notch ligands (Delta-like 1, 3, 4 and Jagged-1 and 2) have 
been discovered. Notch signaling is activated when the Notch ligand binds to an adjacent 
receptor. Upon activation, Notch is cleaved through a cascade of proteolytic cleavages by the 
metalloproteases, tumor necrosis factor α-converting enzyme and γ-secretase. Gamma secretase 
complex releases an active fragment called Notch intracellular domain (NICD). NICD 
translocates to the nucleus and then binds to the transcription factor CSL (CBF1, Suppressor of 
Hairless, and Lag-1). The CSL-NICD complex recruits a co-activator complex containing p300 
and other co-activators leading to the activation of Notch target genes that are important in the 
regulation of cell growth, proliferation and apoptosis (eg. Akt, Cyclin D1, c-Myc, COX-2, 
MMP-9, ERK, mTOR, NF-kB, p21, p27, p53, VEGF) (70, 71).  
Recently, the Notch signaling pathway has been found to directly upregulate Snail-1 and Slug 
thereby inducing EMT (72). Inhibition of Notch 1 signaling in MD-MBA-231 breast cancer cells 
using a monoclonal antibody resulted in EMT inhibition (73). In pancreatic cancer cells, 
knockdown of Notch-2 or midkine (a downstream target of Notch-2) also resulted in EMT 
inhibition (74). Supporting these results, NICD was found to promote EMT with increased Snail 




In addition to the above mentioned signaling pathways, several others, such as NF-κB(76), 
growth factor (77), and TNF-α  (78), are also implicated in EMT induction in various 
carcinomas. The end result of activation of all these signaling pathways is to induce the 
expression of EMT transcription factors (Snail, Slug, Zeb-1, Twist), which in turn decreases 
expression of epithelial markers and increases the expression of mesenchymal markers. 
1.2.3. Epithelial to mesenchymal transition transcription factor 
EMT is governed by master regulators such as the Snail family of zinc finger transcription 
factors, the bHLH transcription factors and the zeb family transcription factors. Together with 
other co-repressors and co-activators, these master regulators decrease expression of epithelial 
markers and increase expression of mesenchymal markers during EMT in development and in 
cancer progression. The mechanism of such dual regulation of target genes by these transcription 
factors is only partially understood (79, 80). 
Snail transcription factors. Snail-1 (Snail), Snail-2 (Slug), and Snail-3 (Smuc) belong to the 
Snail family of zinc finger transcription factors. Of these, Snail and Slug activate EMT during 
development and pathological conditions. All these transcription factors contain highly 
conserved carboxy terminal Cys2His2 (C2H2) type zinc finger motifs. Amino terminuses of these 
transcription factors are divergent in nature. The Snail1/GFI domain at the amino terminus of 
these transcription factors is required for protein stability and transcriptional repression of target 
genes (81). 
Snail and Slug are key mediators of EMT in pancreatic tumor progression. Moderate to strong 
Snail expression was found in 78% of pancreatic cancer cases while Slug was expressed in 50% 
of the cases at a lower level than Snail (82). Snail expression levels in pancreatic cancers 
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correlated with lymph node invasion and distant metastasis (83). In an orthotopic transplantation 
model, Snail-transfected pancreatic cancer cell lines displayed highly metastatic and invasive 
abilities. Snail enabled these pancreatic cancer cell lines to undergo EMT at the invasive front of 
the tumor (83, 84).  
 Mechanisms of EMT regulation by Snail have been studied extensively. Snail acts as a repressor 
of genes involved in the maintenance of epithelial phenotype (E-cadherin, occludin, claudin, and 
cytokeratin-18) with the key target being E-cadherin. On the other hand, Snail activates the 
expression of mesenchymal genes such as vimentin, fibronectin, and N-cadherin. Snail also has 
been shown to regulate expression of genes involved in cell polarity (Crumbs3, Lgl2 and dlg3) 
and apoptosis (P53, BID and DFF40) (85). Among these, E-cadherin is the only known direct 
target of Snail (82, 86). 
The mechanism of E-cadherin repression by Snail is a complex process and it involves several 
co-repressor proteins. Epigenetic modification of the chromatin structure at the promoter region 
of CDH1 gene is the major regulatory event.  The C2H2 type zinc finger domain allows 
sequence-specific binding of Snail to the E-box in the proximal promoter region of the CDH1 
gene, which encodes E-cadherin. Upon binding to the E-box region, Snail recruits co-repressor 
complexes such as   histone deacetylases (HDAC)1/2/Sin3 (86) and polycomb repressive 
complex 2 (PRC-2) (87). HDAC1/2/Sin3 caused deacetylation of H3 and H4 at the CDH1 
promoter resulting in decreased expression of E-cadherin (86). The PRC2 complex catalyzes 
histone 3 lysine 27 trimethylation, which is a hallmark of epigenetically silenced chromatin, 
resulting in decreased expression of E-cadherin (87).  
17 
 
Pharmacological agents that target Snail have been an attractive strategy to inhibit EMT and 
cancer cell metastasis. A cobalt (III) Schiff base complexe ([Co(acacen)(NH3)2]
+)  has been 
shown to inhibit C2H2 zinc finger transcription factors non-specifically. To enhance the 
specificity, an E-box DNA oligonucleotide specifically targeting Snail was attached to the 
acacen equatorial ligand (88, 89). This Co(III)-E-box complex  was a potent inhibitor of Snail- 
mediated transcriptional repression in breast cancer cells and in the neural crest of Xenopus (90). 
However, this complex has not been tested on pancreatic cancer cell lines or in a mouse model 
system.   
Zeb transcription factors. The zinc-finger-enhancer binding protein (Zeb) family of transcription 
factors (Zeb 1 and Zeb2) are one of the best studied EMT inducing transcription factors (91).  In 
PDAC patients, both pancreatic cancer cells and tumor associated stroma showed high level of 
Zeb-1 expression, and Zeb-1 expression was associated with poor prognosis. Inverse correlation 
between E-cadherin and Zeb-1 expression was observed in patient tumor samples, as well as in 
pancreatic cancer cell lines (92, 93). Zeb-1 has been shown to regulate tumor cell invasion and 
migration (94). Silencing Zeb-1 has been shown to reduce cell migration, tumorigenicity and 
tumor dissemination (93, 95, 96). 
Zeb-1 has been shown to decrease transcription of key determinants of epithelial differentiation, 
cell adhesion and cell polarity genes (97). E-cadherin is a well-known direct target of Zeb-1.  
Zeb-1 decreases E-cadherin expression by recruiting HDAC-1/2 or Switch/sucrose non-




A negative feedback loop between Zeb-1 and the microRNA-200 family has been shown in 
regulating EMT (99-101). Zeb-1 is a major target of miR-200c and miR-141, members of the 
miR-200 family. On the other hand, Zeb-1 strongly repress the expression of miR-200 family 
members (102). This suggests that Zeb-1 activates microRNA mediated feed forward loop that 
stabilizes EMT and promotes invasion of cancer cells. Pancreatic cancer patients with a high 
level of miR-200c expression had better survival rates than those with a low-level of miR-200c 
expression. In these patients, there also existed a strong correlation between the levels of miR-
200c and E-cadherin expression (100, 103, 104).  
 Drugs that inhibit Zeb-1 function might have clinical relevance for pancreatic cancer patients. 
Unfortunately, effective small-molecule inhibitors of Zeb-1 are yet to be identified.  
Basic helix loop helix transcription factors (bHLH).  Among all the bHLH transcription factors 
studied, E12, E47, Twist 1 and Twist 2 have been shown to play important roles in EMT (105). 
E-12 and E-47 act as a repressor of E-cadherin expression and trigger EMT.  The mechanism of 
E-cadherin repression by E-12/47 is not well understood (106). Inhibition of differentiation 1 
might be required for E-47 induced EMT (107, 108).  
Twist 1 and Twist 2 are major regulators of EMT during development and pathogenesis (109). 
Twist expression is either absent or very weak in tissue samples from patients with PDAC. 
Pancreatic cancer cell lines also (MiaPaCa-2, PANC-1, Capan-1, HPAF-2 and AsPC-1) showed 
no expression of Twist. However, hypoxic conditions induced Twist expression in MiaPaCa-2, 
PANC-1, Capan-1 and HPAF-2 cell lines (82).  As pancreatic tumors are often under hypoxic 
conditions (110), Twist may play a role in the invasive behavior of pancreatic tumors. 
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Like Snail, Twist interacts with several co-factors to regulate the expression of genes involved in 
EMT. Both E-cadherin and N-cadherin are direct targets of Twist. Twist has differential effects 
on expression of E-cadherin and N-cadherin. It decreases E-cadherin expression but induces N-
cadherin expression. The mechanism of such dual regulation of target gene expression by Twist 
is not completely understood, but it is known that Twist recruits the Set-8 methyl transferase (a 
member of the SET domain-containing methyltransferase family) to the promoter region of E-
cadherin and N-cadherin and enhances H4K20 monomethylation (111). Recently, Fu and 
colleagues showed that Twist interacted with several components of the Mi2/nucleosome 
remodeling and deacetylase complex to repress the transcription of E-cadherin (112). Twist has 
also been shown to specifically interact with BRD4, a bromo domain and extra terminal domain 
protein, to regulate the expression of target genes. Inhibition of BRD4 and Twist interaction by 
small molecular inhibitors such as JQ1 and MS417 suppressed tumor growth in a few animal 
models (113).  
1.3. Cancer stem cells (CSCs) 
Despite recent advances in cancer treatment, many therapies still fail. This results in disease 
progression, recurrence and dismal survival. Recent studies have shown that cancer stem cells 
(CSCs) are the predominant factors that are responsible for tumor recurrence (114). In 1997 
Bonnet and colleagues discovered for the first time that a minor subpopulation of acute myeloid 
leukemia (AML) cells expressing markers of normal hematopoietic stem cells presented the 
potential to propagate AML in immune deficient mice (115). It was therefore hypothesized that 
malignancy originated from mutated stem cells that were transformed to generate daughter 
cancer cells. These tumor-generating subpopulations of cancer cells were later termed stem-like 
cancer cells, or CSCs. Although the biology of CSCs needs to be further understood, the 
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existence of CSCs has been demonstrated in almost all kinds of hematological malignancies and 
solid tumors (116).  
1.3.1. Defining properties of CSCs 
CSCs share a lot of characteristic features with normal stem cells. Normal stem cells undergo a 
specialized cell division termed asymmetric cell division, where each stem cell generates one 
daughter cell with stem cell fate (self-renewal) and one daughter cell (progenitor cell) that is 
destined to differentiate. It is believed that CSCs also have the features of asymmetric cell 
division, where self-renewal capacity helps to maintain the number of CSCs within the tumor 
and its descendent progeny constitute the bulk of the tumor (117).  Supporting this notion it has 
been shown that many pathways (Wnt/β-catenin, Sonic hedgehog, and Notch) that are classically 
associated with cancer may also regulate stem cell self-renewal (118).  
Another most common characteristic feature shared by normal and CSCs is quiescence. 
Mammalian adult stem cells are predominantly in a quiescent, non-dividing G0-state in the 
absence of any extracellular signals (119). CSCs are also characteristically quiescent, and the 
dormancy of this small population protects them from chemotherapeutic drugs that are developed 
to target actively dividing cells, resulting in cancer relapse (117). Late relapse after initial 
treatment in several malignancies is explained with the existence of dormant CSCs (120).  
In addition to the above two characteristic features, CSCs exhibit unique features such as drug 
resistance and metastasis ability. 
1.3.2. EMT drives CSC formation 
The exact relationship between CSCs and metastasis is not clear yet. It might lie in the close 
association of CSCs with cancer cell EMT.  EMT and CSCs share many signaling pathways, 
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such as Wnt/β-catenin and Notch signaling pathway. Induction of EMT generated cells with 
stem-like properties in HMLER breast cancer cells , either by over expressing Twist or Snail 
(121), or by inhibiting the expression of E-cadherin using shRNA (122). Harvey rat sarcoma 
viral oncogene homolog (H-Ras) overexpression induced EMT in human mammary epithelial 
cells (HMECs) and concurrently induced enrichment of CD44+CD24- HMECs, which were 
considered as stem-like cells (123). Conditioned media from activated fibroblasts induced EMT 
and increased CSCs in PC-3 prostate cancer cells by releasing MMP-2 (124). In a mouse model, 
it was shown that circulating pancreatic cancer cells maintained a mesenchymal phenotype and 
exhibited stem cell properties (53). The circulating cancer cells are considered equivalent to 
stem-like cancer cells. Overexpression of other EMT inducers, such as FoxM1 and Notch-1, also 
resulted in enrichment of pancreatic CSCs (125).  
1.3.3. Pancreatic CSCs are highly metastatic and resistant to chemotherapeutic drugs  
CSCs not only possess self-renewal capacity, but also have the potential and the ability to invade 
and metastasize to secondary sites. Herman and colleagues showed that the subset of CXCR4+ 
CD133+ pancreatic CSCs exhibited strong migratory potential and showed liver metastasis in an 
orthotropic model system. However, CXCR4+ CD133- cells representing the non-cancer stem 
cell population failed to undergo liver metastasis (126). Inhibition of c-Met, a marker of 
pancreatic cancer CSCs, using cabozantinib (a small-molecule inhibitor of the tyrosine kinases c-
Met), decreased tumor growth and metastasis (127).  
CSCs play an important role in cancer drug resistance, which often impairs the successful use of 
chemotherapies (126, 128, 129). The mechanism by which CSCs become drug resistant is largely 
unknown, but it is very likely that ATP binding cassette (ABC) drug transporters are involved. 
Wang et al. showed that CSCs gain drug resistance partly due to over expression of ABCG2 
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(BCRP) (130). ABCG2 pumps cytotoxic drugs out of cancer cells resulting in protecting tumor 
cells from chemotherapeutic drugs (131). In another study, Hong and colleagues found that 
CD44+ CSCs that were expanded during the acquisition of gemcitabine resistance, showed 
significantly elevated levels of ABCB1 (MDR1). The ABC transporter inhibitor, verapamil, 
resensitized the resistant cells to gemcitabine (132). It is also very likely that CSCs drug 
resistance is caused by both intrinsic and acquired properties such as quiescence, detoxifying 
enzymes, DNA repair ability and overexpression of anti-apoptotic proteins (133). Understanding 
the biology of drug resistance related to CSCs is necessary and would provide clues to design 
novel therapeutic options. 
1.3.4. Markers used to study pancreatic CSCs 
Several cellular markers or their combinations have been used to identify pancreatic CSCs.   
These include aldehyde dehydrogenase (ALDH) (134, 135), CD133 (136) and the combination 
of CD133+ CXCR4+ (CXC chemokine receptor 4) (126). Li et al. proposed usage of CD44+ 
CD24+ EpCAM+ as markers for pancreatic CSC because CD44+ CD24+ EpCAM+ pancreatic 
cancer cells showed properties of self-renewal and the ability to produce differentiated progeny 
(137). Other markers such as c-Met (127), doublecortin-like kinase 1 (138), and CD44v6 (139) 
were also proposed as putative pancreatic CSC markers. Although none of the proposed markers 
definitively identify a pure population of pancreatic CSCs, these markers are used widely 
because they provide consistent data for a strong enrichment of pancreatic CSCs. 
1.3.5. Assays to measure CSCs 
The gold standard assay to measure the self-renewal and lineage capacity of CSCs is serial 
transplantation in animal models. Cells are injected into the orthotopic site of NOD/SCID mice 
which are then assayed at different time points for tumor formation. Cells isolated from the 
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tumor are xenografted into a second recipient animal to measure the self-renewal capacity. 
However, this serial transplantation model is costly and time consuming, and is therefore not 
feasible to be used in drug screening (140).    
An  in vitro spheroid formation assay has been widely used to determine the self-renewal 
capacity of CSCs.  The assay is based on the principle that only CSCs survive in suspension 
culture with non-stem cells die by anoikis. The ability to form several generations of spheres in 
serial non-adherent passages is related to the self-renewal ability of CSCs. For example, the 






 cells did not.  The CD44+CD24+EpCAM+ pancreatospheres can be passaged 
multiple times without loss of the tumor sphere-forming capability (141).   
1.3.6. Interplay of multiple cellular signaling pathways triggers pancreatic CSCs 
The understanding of the molecular mechanism by which CSCs are formed will benefit not only 
basic research but also clinical cancer therapy. Recent studies have demonstrated that the 
formation of CSCs can be triggered and maintained by the interplay of multiple cellular signaling 
pathways, including Notch, Hedgehog, and Wnt/β-catenin (142).  
Notch-signaling pathway plays an important role in maintaining CSC population.  Pancreatic 
CSCs expressed considerably higher levels of Notch-1 than the rest of the cancer cell population 
(143).  Notch-1 over expression in pancreatic cancer cell lines induced EMT and increased the 
formation of pancreatospheres, which are indicative of CSCs (144). Activation of Notch pathway 
with an exogenous Notch peptide ligand increased the percentage of CSCs (145). However, 
further investigation is required to elucidate the molecular mechanism that explains how Notch 
signaling regulates pancreatic CSC self-renewal. 
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Hedgehog signaling pathway in maintaining CSC population. The Hedgehog (HH) pathway 
plays a critical role in the processes of embryonic development and maintenance of CSCs (146). 
The HH signaling pathway consists of HH ligands (Sonic HH, SHH; Indian HH, IHH; and 
Desert HH, DHH), Patched proteins (Patched-1 and 2), Smoothened (Smo), inhibitory complex 
(Fused, Suppressor of Fused) and the 5-zinc-finger transcription factors, Gli1, Gli2 and Gli3. In 
the absence of HH ligand, Patched-1 and 2 suppresses Smo. In the presence of HH ligand, 
inhibition of Smo by Patched is released, providing a signal for the dissociation of Gli 
transcription factor from the inhibitory complex. Dissociated Gli  translocates to the nucleus and 
regulates the transcription of target genes such as Cyclin D1, N-Myc and p21, Wnt, Patched and 
Gli itself (147, 148). 
Deregulation of HH signaling has been observed in most cancers (149). Transgenic mice with 
overexpression of SHH in pancreatic epithelium developed PanIN lesions, suggesting that SHH 
might be an early mediator of pancreatic cancer tumorigenesis (149).  Two independent studies 
showed that pancreatic CSCs had more than 40-fold higher SHH expression than the non-CSC 
population (137, 150), suggesting that SHH might maintain CSC self-renewal.  Slow cycling 
stem-like cells that exhibited higher tumorigenic potential had up-regulation of HH and TGF-β 
signaling pathways (151). Therefore, inhibition of HH signaling might be an alternative 
therapeutic approach for pancreatic cancer patients. 
Wnt/β-catenin signaling pathway in maintaining CSC population. Wnt/β-catenin signaling 
plays an important role in CSCs of a variety of cancers.  For example, constitutively activated β-
catenin signaling in stem cells is essential for intestinal neoplasia (152). Wnt-1 overexpression 
enhanced the sphere formation capacity of the gastric cancer AGS cell line (153). The canonical 
β-catenin signaling pathway is the most significantly deregulated signaling pathway in 
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glioblastoma stem cells (154), it is also required for self-renewal of leukemia stem cells that were 
derived from either hematopoietic stem cells or from granulocyte-macrophage progenitors (155). 
The roles of Wnt/β-catenin signaling in pancreatic CSCs deserve further investigation.  
1.4. Current Treatment for pancreatic cancer 
Current treatment for pancreatic cancer is far from satisfactory. As advancements in molecular 
and targeted therapies have greatly improved survival of patients with many types of cancers, the 
treatment outcome for pancreatic cancer has not changed much over the past 30 years. In the last 
a few decades of the 20th century,  five fluoro uracil (5-FU) was the standard of care for 
pancreatic cancer patients (156). In 1997, a randomized phase 3 study demonstrated a survival 
benefit for gemcitabine (2′, 2′-difluoro 2′-deoxycytidine) over 5-FU (157). Since then, 
gemcitabine as mono-treatment has been the standard of care for pancreatic cancer patients. 
Gemcitabine, is an analog of cytosine exhibited distinctive pharmacological properties (with 
multiple intracellular targets such as DNA polymerase, ribonucleotide reductase, cytidine 
triphosphate synthetase, deoxycytidylate deaminase) and a wide spectrum of anti-tumor activity 
(158). However, gemcitabine has little impact on median overall survival for patients with 
locally advanced or metastatic pancreatic cancer, who comprise the majority of cases (159, 160). 
Many studies used gemcitabine in combination with other chemotherapeutic drugs intending to 
improve the median survival in pancreatic cancer patients. However, the improvement has not 
been satisfactory.  Gemcitabine in combination with either capacitance (prodrug of 5-FU, a 
pyrimidine analog) (161) or platinum drugs (cisplatin, carboplatin) (162, 163) did not result in 
significant improvement in overall survival. A combination of gemcitabine and nab-paclitaxel 
(164) improved overall survival, progression free survival and response rate compared to 
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gemcitabine treatment alone. However, peripheral neuropathy and myelosuppression were 
significantly increased (165).  
Surgical resection is the only curative therapy for pancreatic cancer patients with localized 
disease (166). However, only 15–20% of patients have resectable disease at the time of 
diagnosis. Patients who undergo surgery (Whipple procedure) have a perioperative mortality of 
4-18% and an additional risk of post operational complications (4, 167, 168). Furthermore, the 
majority of the patients have locally invasive and micro metastasis at the time of surgery. 
Therefore, disease recurrence following operation is very high. Adjuvant therapy (5-FU or 
gemcitabine-based chemoradiation) is specified to decrease the risk of loco-regional and 
metastatic recurrence (169). 
Recently, FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin), as the first 
gemcitabine free regimen, has been shown to be more efficient than gemcitabine. The median 
overall survival was 11.1 months in the FOLFIRNOX group as compared with 6.8 months in the 
gemcitabine group.  Side effects of this new combination regimen were significant, including 
grade 3 and 4 neutropenia, suggesting a limited use for patients with good performance status 
(170). 
1.5. Investigational chemotherapies for pancreatic cancer 
Pancreatic cancer is a multifactorial complicated disease. Conventional chemotherapies or 
radiation therapies often yield disappointing results and are largely ineffective in depleting 
CSCs, which are responsible for disease recurrence. Therefore, new innovative treatment options 
need to be tested. As the understanding of pancreatic cancer biology and pathophysiology 
increases, several novel approaches for targeted therapies are currently under investigation. In 
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the following paragraphs some of the investigational therapies that have potential clinical success 
for pancreatic cancer patients are summarized. 
1.5.1. Targeting K-Ras 
K-Ras is an attractive therapeutic target because it is mutated in the vast majority of PDAC 
cases.  An ideal mechanism to prevent K-Ras signaling would be to directly block the GTP-
binding site of K-Ras. However, there has not been an effective small-molecule inhibitor 
identified. Alternatively,  other approaches have been investigated to  1) block membrane 
localization of K-Ras, 2) block Son of Sevenless (SOS)/K-Ras interactions, and 3) block K-Ras 
downstream effector targets such as PI3K, Raf, MEK 1/2 and Akt (171). 
Blocking K-Ras membrane localization.  Membrane localization of K-Ras brings it into contact 
with Ras activating protein to activate downstream signaling (172). Following translation, K-Ras 
undergoes a lipid modification called farnesylation and/or geranylgeranylation (together referred 
as prenylation). Phosphodiesterase delta (PDEδ) is a prenyl binding protein and interacts with 
prenylated K-Ras to aid K-Ras to translocate to the membrane (173, 174). It was hypothesized 
that inhibition of farnesylation and or geranylgeranylation would prevent K-Ras membrane 
localization, thus inhibiting its signaling pathway. A number of inhibitors for farnesyl transferase 
(FTIs) and geranylgeranylation transferase (GGTIs) were synthesized and tested for their anti-
tumor activity (175-180). At least six FTIs have been tested in clinical trials, but unfortunately 
have predominantly proven unsuccessful for K-Ras driven tumors (181-183). A 
geranylgeranylation transferase inhibitor, GGTI-2418 is currently in phase-1 clinical evaluation 
(http://www.prnewswire.com/news-releases/first-patient-dosed-in-phase-i-clinical-trial-of-tigris-
pharmaceuticals-ggti-2418-61683932.html).  The combination of FTI and GGTI induced greater 
apoptotic response in cancer cells than a single agent alone, but high toxicities limited their 
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clinical use (184). Deltarasin, inhibited PDEδ and K-Ras interactions and K-Ras membrane 
localization, suppressed in vitro and in vivo proliferation of PDAC cells (185). Salirasib (S-trans, 
trans-farnesylthiosalycilic acid) dislodged K-Ras from the membrane thereby promoting K-Ras 
degradation. In a patient derived xenograft model, salirasib showed a wide range of activity and 
showed a heightened tumor response when combined with gemcitabine (186). Salirasib is under 
clinical investigation (186). 
 Blocking SOS/K-Ras interactions. At the membrane, K-Ras is activated by SOS (guanine 
nucleotide exchange factor), which aids in K-Ras binding to GTP. Blocking these interactions 
potentially inhibits K-Ras signaling pathway (187). Using an NMR based fragment-screening 
approach, Maurer and colleagues identified 4, 6-dichloro-2-methyl-3-aminoethyl-indole as a 
small-molecule compound that blocked the interaction between K-Ras and SOS and inhibited the 
nucleotide exchange (188). Later, several other compounds were discovered which were shown 
to bind GDP-bound K-RasG12D and to inhibit SOS catalyzed nucleotide exchange (189). Anti-
cancer activities of these compounds need to be investigated in preclinical and clinical studies.  
Blocking K-Ras downstream effector targets. Effector pathways are activated downstream of K-
Ras in a context- and tissue-specific manner. MAPK and PI3K-Akt signaling pathways are the 
two most commonly activated signaling pathways in pancreatic cancer. Efforts have been made 
to develop pharmacological agents targeting MAPK and PI3K-Akt signaling pathways. The 
MAPK pathway consists of a kinase cascade, where K-Ras activates Raf kinases, which in turn 
activate MEK1/2 (187). In preclinical models, MEK inhibitor PD325901 reduced tumor burden 
and prolonged survival time and showed a synergistic effect with Akt inhibitor GSK690693 
(190). In a patient derived xenograft model, another MEK inhibitor, trametinib (GSK1120212) 
reduced tumor mass. Trametinib (MEK inhibitor) and lapatinib (EGFR/HER2 inhibitor) 
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combination treatment resulted in significantly enhanced inhibition of tumor growth compared to 
trametinib alone (191). PI3K and Akt inhibitors were also tested in preclinical models and 
showed potent anti-cancer activity (17, 190). These results suggest that blocking K-Ras 
downstream targets is a potential therapeutic option for pancreatic cancer patients who harbor K-
Ras mutations. 
Utilizing high-throughput screening strategies, researchers have made efforts to develop drugs 
that specifically kill cells expressing mutant K-Ras. Several high-throughput screening assays 
have been performed using cells harboring K-Ras mutation and its isogenic cells without K-Ras 
mutation. Compounds showing selective lethality against K-Ras mutant transformed cells were 
identified, including sulfinyl cytidine and its derivative triphenyltetrazolium (192), oncrasin-1 
(193), tolperisone and its derivative lanperisone (194),  and  SLI501 (195). These compounds are 
under preclinical and clinical testing. Success of the clinical studies on these compounds would 
change the shape of pancreatic cancer treatment. 
1.5.2. Histone deacetylase (HDAC) inhibitors.  
A growing body of literature suggests that deregulation of histone deacetylases (HDACs) could 
contribute to pancreatic cancer development and progression (196-199). HDACs play critical 
roles in the epigenetic regulation of gene expression by catalyzing the removal of acetyl groups 
from histones, causing compaction of the DNA/histone complex. This compaction blocks gene 
transcription and inhibits differentiation (200, 201). In eukaryotic cells, 18 different HDACs 
have been identified and are classified into 4 groups based on their homology to yeast proteins. 
Class I includes HDAC 1, 2, 3, and 8 and are exclusively located in the nucleus. Class IIa 
includes HDAC 4, 5, 7 and 9 and are localized to the cytoplasm. HDAC 6 and 10 belong to class 
IIb and HDAC 11 is classified in class IV.  HDAC 11 is localized in both cytoplasm and nucleus. 
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Classes I, II, and IV HDACs are Zn-dependent enzymes. Class III HDACs include sirtuins, 
which are NAD+ dependent enzymes and have homology to yeast Sir2 (201-203). 
Overexpression of HDAC isoenzymes has been observed in several cancers (204). In pancreatic 
cancer, overexpression of  HDAC 1,  (198), HDAC 2 (196), and  HDAC7  (197), and  HDAC 3 
(199) were observed. As described before, HDACs also involve in Snail mediated EMT process. 
Thus, targeting HDACs by inhibitors could be a promising strategy for pancreatic cancer 
treatment.  
To date, more than 15 HDAC inhibitors have been tested in preclinical and early clinical studies. 
Based on the chemical structure, HDAC inhibitors are classified in into 4 different classes: 
hydroxamates (e.g. suberanilohydroxamic acid (SAHA) and panobinostat), cyclic peptides (e.g. 
romidepsin), aliphatic acids (e.g. sodium butyrate, valproic acid and phenyl butyrate) and 
benzamides (e.g. entinostat or known as MS-275 and mocetinostat) (201).  The Food and Drug 
Administration approved SAHA for the treatment of cutaneous T-Cell Lymphoma (CTCL). In 
animal models, SAHA in combination with bortezomib (proteasome inhibitor) or Zebularine 
(nucleoside analog of cytidine) reduced pancreatic tumor weight with minimal noted toxicity 
(205, 206). SAHA also reduced migration, colony formation and sphere formation ability of 
pancreatic CSCs. Specifically, SAHA inhibited the expression of Zeb-1, Snail, and Slug, 
suggesting that SAHA inhibited EMT in pancreatic CSCs. Furthermore, SAHA inhibited the 
Notch signaling pathway by upregulating miR-134 (207). Other HDAC inhibitors like MS-275, 
TSA and FK228 showed potent anti-tumor effects both in vitro and in vivo (208). However, all 
these HDAC inhibitors so far showed limited or no efficacy in clinical trials in solid 
malignancies including PDAC, when used as monotherapy (209-211), or in combination with 
other chemotherapeutic drugs (212-215).  
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The lack of effects might partially come from the non-specificity of current HDAC inhibitors. 
Majority of the HDAC inhibitors in clinical trials inhibit all HDAC isoforms nonspecifically 
(pan inhibitors). Such nonspecific inhibition leads to many toxic side effects that limited the dose 
that can apply (216). Selective HDAC inhibitors, which affect a single HDAC isoform, would be 
ideal chemical tools to elucidate the functions of each individual HDAC isoform.  Also, 
development of class-selective HDAC inhibitors might provide more effective HDAC inhibitors 
than the pan HDAC inhibitors.  
1.5.3. Targeting pancreatic CSCs for therapy.   
Reactivation of developmental signaling pathways (Notch, SHH) is involved in the formation of 
CSCs (217). Inhibitors of these signaling pathways could be valuable tools to target CSCs.  
Hedgehog (HH) inhibitors.  Several small-molecule HH inhibitors are under preclinical and 
clinical development (218). For example, the HH inhibitor cyclopamine inhibited pancreatic 
cancer cell EMT, CSCs, and reduced metastasis in an orthotopic xenograft mouse model (219). 
Cyclopamine down regulated the expression of CSC markers CD44, and CD133 in gemcitabine 
resistant pancreatic cancer cells and restored gemcitabine sensitivity (220). In combination with 
the mTOR inhibitor, rapamycin, cyclopamine reduced the number of pancreatic CSCs to 
undetectable levels in vitro and in vivo (221). IPI-269609 and GDC-0449, two other small-
molecule inhibitors of the HH signaling pathway, also effectively depleted pancreatic CSCs 
(222, 223). Recently, Balic and colleagues found that the anti-malarial agent chloroquine (CQ) 
significantly decreased pancreatic CSCs by inhibiting the HH signaling pathway (224). They 
further showed that CQ in combination with gemcitabine improved the overall survival of mice 
bearing PDAC patient derived xenografts.  
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However, these preclinical results were not recapitulated in clinical trials. A single arm pilot 
study in 25 metastatic PDAC patients was conducted to study the effect of GDC-0449 plus 
gemcitabine. The treatment resulted in inhibition of the HH signaling pathway, without 
significant changes in CSCs, fibrosis, progression free survival and overall survival. However, 
grade ≥3 toxicities in 56% of patients were observed. This pilot study concluded that GDC-0449 
and gemcitabine were not superior to gemcitabine alone in the treatment of metastatic pancreatic 
cancer (225). Similarly, a double-blind, randomized phase 2 study, IPI-926 plus gemcitabine or 
gemcitabine plus placebo, showed no improvement in overall survival 
(http://www.businesswire.com/news/home/20120127005146/en/Infinity-Reports-Update-Phase-
2-Study-Saridegib#.VXGcwcvwvcs). A phase 2 GDC-0449 plus gemcitabine or gemcitabine 
plus placebo study also showed no statistical improvement in progression free survival and 
overall survival (https://clinicaltrials.gov identifier: NCT01064622).  
Reasons for the failure of HH inhibition in PDAC patients were explored using a genetically 
engineered mouse model (GEMM) (226). In this GEMM, either loss of SHH or pharmacological 
inhibition using IPI-926 was associated with decreased survival, higher frequency of gross 
metastasis. SHH deficient tumors had reduced stromal content, and increased blood vessel 
density (226). Therefore, SHH inhibitors warned for further clinical use in PDAC patients.  
 Notch inhibitors.  Gamma secretase activates the Notch signaling pathway. Hence γ-secretase 
inhibitors (GSI) are attractive inhibitors for CSCs. The GSI MRK-003 effectively inhibited 
intratumoral Notch signaling and prolonged survival of tumor bearing mice when combined with 
gemcitabine (227). Pretreatment of PDAC cells with MRK-003 in cell culture significantly 
inhibited pancreatic CSCs and subsequent tumor formation in immunocompromised mice (228). 
PF-03084014, a selective GSI, was also shown to induce pancreatic tumor regression by 
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depleting CSCs (229). Inhibition of Notch singling pathway using either GSI (RO4929097) or 
Hes1 ShRNA reduced both in vitro sphere formation and in vivo tumor growth of orthtopic 
pancreatic tumors (145). A Phase 2 study was completed recently using RO4929097 in 
previously treated metastatic pancreatic cancer patients and showed no potential advantage over 
gemcitabine (https://clinicaltrials.gov identifier: NCT01232829). PF-03084014 recently entered 
into a phase 1/2 study in combination with gemcitabine and Nab-paclitaxel in patients with 
previously untreated metastatic PDAC (https://clinicaltrials.gov identifier: NCT02109445). A 
phase 3 study of gemcitabine plus Nab-paclitaxel combination showed slight improvement in 
survival (8.5 months, statistically significant) compared to gemcitabine (6.7 months) (165). 
Adding PF-03084014 to this combination is in hope to further improve the survival.  
Other potential approaches to target pancreatic CSCs. Targeting the cell-surface antigens that 
are characteristic to CSCs is an attractive strategy to eliminate pancreatic CSCs. Specific 
monoclonal antibody targeting CD44, eliminated leukemic stem cells by inducing terminal 
differentiation (230). Inhibition of c-Met, a marker of highly tumorigenic CSCs has been found 
to inhibit tumor growth and metastasis (127). A bispecific antibody that recognizes both 
epithelial surface antigen (EpCAM) and CD3 has been shown to eliminate pancreatic CSCs 
(231). Monoclonal antibodies targeting CD44, EpCAM and c-Met needs to be tested in clinical 
trials. 
The anti-cancer agents from diet or natural plants (e.g. genistein, curcumin, resveratrol) have 
been found to inhibit CSCs self-renewal through modulation of important signaling pathways, 
thus leading to inhibition of pancreatic cancer development and progression (232). Genistein, 
one of the isoflavones found in soybeans, strongly inhibited the growth of leukemic 
hematopoietic progenitor cells and ovarian CSCs , and  inhibited the pancreatospheres in vitro by 
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down regulating the Notch signaling pathway (144, 233-235). In another study, Bao and 
colleagues also reported that genistein inhibited EMT, which is highly associated with CSCs 
(125). Curcumin, a bioactive compound found in the Curcuma longa, can inhibit CSCs in 
various human cancers (236, 237). Curcumin and 3, 4-difluoro-benzo-curcumin, a novel 
synthetic analog of curcumin, inhibited the sphere formation ability of pancreatic cancer cell 
lines and attenuated the pancreatic CSC markers CD44 and EpCAM (238). Curcumin was 
reported to decrease the CSC population by targeting the histone methyl transferase, enhancer of 
zeste homolog 2 miRNA regulatory circuit (239). Resveratrol showed a potent anti-cancer effect 
on various types of cancers, including pancreatic cancer (240) by modulating Src, STAT3, and 
FOXO (241, 242). Resveratrol inhibited the self-renewal capacity of pancreatic CSCs derived 
from K-Ras transgenic mice and from human primary tumors. Moreover, resveratrol decreased 
the expression of pluripotency maintaining factors such a Sox-2, c-Myc, Nanog and Oct-4 in 
pancreatic CSCs and induced CSCs apoptosis through activation of caspase-3/7 (243).  
Clinical studies have been carried out on some of these dietary compounds so far showed little 
benefit over gemcitabine treatment.   
A phase 2 trials of curcumin in patients with advanced pancreatic cancer showed good tolerance 
and biological activity in 2 out of 21 patients.  One patient had stable disease for >18 months. 
Another patient had marked tumor regression (73%) (244). Two other studies investigated 
curcumin in combination with gemcitabine in patients with advanced pancreatic cancer. The 
results suggested that curcumin and gemcitabine combination did not provide survival advantage 
(median survival 5.3 and 6 months in the two trials, respectively) (245, 246). A phase 2 study 
adding genistein to gemcitabine and erlotinib combination in advanced pancreatic cancer 
patients,  resulted in no significant improvement than gemcitabine and erlotinib combination 
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(247, 248).  As for resveratrol, studies so far indicated it is a promising cancer preventing agent 
instead of chemotherapeutic agent (249).  
Taken together, many efforts have been made targeting various molecular pathways using either 
pharmacological agents or nutraceuticals to inhibit pancreatic cancer growth, metastasis and 
CSCs. Despite many preclinical advancements, it remains a huge challenge to find a clinically 
effective therapeutic agent. In this dissertation we used several novel approaches to target 

































The purpose of this study is to investigate innovative and promising inhibitors of pancreatic 
cancer EMT. We hypothesized that identification of novel and potent compounds that inhibit 
EMT holds the potential to inhibit metastasis and CSCs in pancreatic cancer.  We performed 
studies to test the central hypothesis through the following specific aims. 
2.1. Specific aim 1: To investigate the mechanisms of high-dose parental ascorbate as a 
novel inhibitor for pancreatic cancer EMT. High dose ascorbate (Asc) is a widely used 
regimen in complementary and alternative medicine as a cancer treatment. The scientific basis 
for this use was recently revealed. In a PANC-1 orthotopic mouse model, ascorbate significantly 
reduced tumor progression, metastasis and final tumor weight. Consistently, a matrigel invasion 
assay demonstrated in vitro that ascorbate reduced PANC-1 cell migration and invasion. As 
EMT is highly associated with cancer cell metastasis, we investigated the effect of ascorbate on 
EMT regulation. We further studied the mechanisms of ascorbate-mediated regulation of 
pancreatic cancer cell metastasis, focusing on tumor microenvironment and tumor cell 
microtubule dynamics, which are also associated with cancer cell metastasis. Methods including 
western blot, real time PCR, native polyacrylamide gel electrophoresis, immunofluorescence, 
gelatin zymography, trichrome staining, and HPLC were used to achieve the goals of specific 
aim 1.  
2.2. Specific aim 2: To investigate novel derivatives of HDAC inhibitors as inhibitors for 
pancreatic cancer EMT. HDAC inhibitors could inhibit EMT through histone modification. 
However, in patients with solid tumors, current HDAC inhibitors have not shown significant 
efficacy. Hence, the development of more efficacious and less toxic HDAC inhibitors for 
treating pancreatic cancer remains an important goal to improve anticancer therapy. The 
development of analogues and derivatives is a commonly used approach for new drug 
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development in order to improve potency, bioavailability, and to reduce toxicity. In the current 
study, we studied the efficacy and mechanism of action of novel derivatives of HDAC inhibitors 
SAHA and MS-275, using MTT assay, western blot, sphere formation assay, fluorescence 
activate cell sorter, Boyden chamber invasion assay, real time PCR, fluorescence polarization 
assay and amplified luminescent proximity homogeneous assay (Alpha) assay.  
2.3. Specific aim 3:  To establish a high-throughput screening method for identification of 
EMT and CSC inhibitors. Large scale screening for CSC inhibitors would be an efficient way 
for discovery of drugs targeting CSCs. However, to date there still lacks a highly efficient and 
feasible approach for such screening, because CSC only compromise a small portion of the bulk 
cancer cell population, and it is difficult to maintain an undifferentiated CSC culture. Loss of E-
cadherin is a key initial step in the trans-differentiation of epithelial to a mesenchymal 
phenotype. In this study, we established an immunofluorescent high-throughput screening (HTS) 
assay to identify compounds that induce E-cadherin expression. . Based on the close relationship 
of EMT and CSC, we tested the hypothesis that this approach for identifying EMT inhibitors 
could be useful for discovery of CSC inhibitors. Chemical screening was conducted on PANC-1 
cells utilizing 4 chemical libraries (Prestwick, MicroSource, ChemBridge and the University Of 
Kansas Center Of Excellence in Chemical Methodologies & Library Development) containing 
total of 41,472 small organic molecules with structural diversity and drug like properties to 
detect E-cadherin inducers. Positive hits were then validated for EMT inhibition in pancreatic 
cancer cell lines, using western blot, Boyden chamber invasion assay and scratch assay. Ability 





























3.1. Cell culture and viability assay 
Immortalized human pancreatic ductal epithelial cells (hTERT-HPNE) were provided by Dr. 
Shrikant Anant (University of Kansas Cancer Center, Kansas City, KS). Human pancreatic 
cancer cell line L3.6 was provided by Dr. Liang Xu (University of Kansas, Lawrence, KS).  
Mouse syngeneic pancreatic cancer cell line Pan02 was donated by Dr. Anthony Sandler 
(Children’s National Medical Center, Washington, DC). Human lymphocytes were isolated by 
apheresis at Dr. Mark Levine’s lab (National Institute of Diabetes and Digestive and Kidney 
Diseases, National Institutes of Health, Bethesda, MD). All other cell lines were obtained from 
the American Type Culture Collection (Manassas, VA). All cells were cultured in recommended 
media supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin/streptomycin at 
37 °C in a humidified 5% CO2 atmosphere.  
MTT (4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay was used in 
determining cell viability as described (250). In short, Cells were plated onto 96 well plates at a 
starting density of 10,000 cells and treated with different chemical compounds as specified in 
each experiment. After incubation for indicated time in specific experiment, treatment media was 
subsequently removed and replaced with 100 µl of 0.5 mg/ml MTT solution in cell culture media 
and incubated for 2-3 hrs at 37 °C in a humidified 5% CO2 atmosphere. Cell viability was 
quantified by measuring the soluble purple color formazan crystals at an absorbance wavelength 
of 570 nm on kinetic micro-plate reader (BioTek, Winooski, VT). 
3.2. Orthotropic mouse model for pancreatic cancer 
All procedures were performed following the animal care and use protocol approved by the 
Institutional Animal Care and Use Committee at the University of Kansas Medical Center. 
PANC-1 cells were transfected with the lentivirus-expressing luciferase gene (PANC-1–Luc) 
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which was developed at Preclinical Proof of Concept Core Laboratory (University of Kansas 
Medical Center, Kansas City, KS). While under anesthesia, a small subcostal laparotomy was 
performed on 4-6 week old Female Ncr nu/nu mice, and then 2 × 105 PANC-1 cells injected into 
the tail of pancreas. Mice were imaged a week after cell implantation to monitor tumor 
formation. To image, each mouse was given 150 mg/kg D-luciferin by intraperitoneal injection. 
Animals were scanned using an IVIS imaging system (Waltham, MA). Mice were grouped based 
on initial tumor burden and then were treated with compounds specified. Mice were imaged 
longitudinally. Treatment typically lasted for 45 days. At necropsy, total tumor burden were 
weighed and metastatic lesions were counted. Tissue samples were fixed in formaldehyde or 
spot-frozen on dry ice and stored at -80oC for further analysis. 
3.3. RNA isolation, cDNA synthesis, and Real-Time PCR 
Total RNA was extracted from cells or tissue samples by using TRIZOL reagent according to the 
protocol of the manufacturer (Invitrogen, Grand Island, NY). cDNA synthesis was performed 
with 1µg of total RNA using Omniscript RT kit according to manufacturer’s protocol (Quiagen, 
Valencia, CA). cDNA was diluted 1:5 (or as indicated in specific experiment) in autoclaved 
nanopure water and used for further analysis. Real-time PCR was performed using Bio-Rad iQ 
iCycler detection system with iQ SYBR green supermix (Bio-Rad Laboratories Ltd, Hercules, 
CA). Reactions were performed in a total volume of 10 µl, including 5 µl of 2X iQ SYBR green 
supermix, 1µl of primers at 20 pmol/µl and 1 µl of cDNA template. All reactions were carried 
out in at least triplicates for every sample. Data were normalized to 18S rRNA.  
3.4. Matrigel invasion assay 
Cells were seeded into inserts of Boyden chambers (BD Biosciences, San Jose, CA) that were 
either pre or not coated with matrigel (0.1 mg/mL), at 1 x 104 cells per insert in 0.5% FBS 
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containing medium, unless otherwise described in specific experiment. Media in wells contained 
10% FBS was used as chemo-attractor. After incubation for indicated time in specific 
experiment, cells that invaded to the bottom-side of the membrane were fixed with 4% para 
formaldehyde for 2 min, permeabilized with 100% methanol for 20 min, followed by staining 
with 0.05% crystal violet for 15 min at 37oC. Non-invading cells on the top side of the 
membrane were removed by cotton swab. Photographs were taken from five random fields per 
insert. Cells in the five random fields were counted. 
3.5. Masson’s trichrome staining  
Collagen content in the tumor and liver sections was detected by using Masson’s trichrome stain 
kit (Sigma, St. Louis, MO) following manufacturer’s protocol. The cytoplasm was stained a pink 
to red color and the collagen was stained blue. 
3.6. Gelatin zymography 
Supernatant media from cell culture was subjected to electrophoresis on 10% SDS poly acryl 
amide gel containing 0.2 % gelation (Sigma, St. Louis, MO). After adequate rinse in rinse buffer 
(1M Tris pH8.0, 1M CaCl2, 2.5% Triton X-100), the gel was equilibrated for 30 min in 
incubation buffer (1M Tris pH8.0, 1M CaCl2), and then was incubated in fresh incubation buffer 
at 37°C for 16 hrs. The gel was stained with Coomassie Brilliant Blue R-250 (Bio-Rad, 
Hercules, CA) for 1-2 hrs, and then destained in 10% methanol and 5% acetic acid. Areas 
corresponding to MMP activity appeared as clear bands against a dark blue background. The 
clear bands were analyzed by optical densitometry by Image J software. 
3.7. Immunofluorescence and immunohistochemistry  
Cells grown on 96 well plates were treated and then fixed in 4% paraformaldehyde, and blocked 
in blocking buffer (1X PBS+5% Goat serum+0.3%Triton X-100) at room temperature for 1hr. 
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Anti-acetylated α-tubulin (1:4000 dilution in 1XPBS+1% bovine serum albumin (BSA)+0.3% 
triton X-100) was incubated at 4oC for overnight. Alexa flour 488-conjugated secondary 
antibody (1:500) was incubated for 2 hrs in dark.  Nuclei were visualized with 1 mg/mL 
Hoechst33342.  
Paraffin-embedded tumor sections (5 µM thick) were deparaffinized and rehydrated by serial 
incubation in xylene, 100%, 95% ethanol, and water. Endogenous peroxide was blocked with 3% 
hydrogen peroxide (H2O2) at room temperature for 10 min. Antigen retrieval was performed in 
boiling citrate buffer for 5min followed by sub boiling temperature for 10min. Anti-PCNA 
primary antibody (1:1000, Cell Signaling Technology, Beverly, MA) was incubated overnight at 
4oC. Biotinylated secondary antibody and DAB were used to develop the tissue sections 
(Vectastain ABC-AP kit, Vector Laboratories, Burlingame, CA). All the sections were 
counterstained with hematoxylin. 
3.8. Gene transfection  
PANC-1 cells were engineered to overexpress a flag tagged HDAC6. Recombinant Plasmid 
pcDNA3.1+-HDAC6-flag and the empty vector pcDNA3.1+ were purchased from Addgene 
(Cambridge, MA). Plasmids were transfected into the PANC-1 cells with lipofectamine TM 2000 
reagent (Invitrogen, Grand Island, NY) according to manufacturer instructions. G418 was used 
for selection of positive clones. Optimal dose of G418 was determined by MTT assay (IC50 = 
0.625 mg/ml). Thirty-six hours after transfection, cells were passaged and were cultured in 
DMEM medium containing 10% FBS and 1 mg/ml G418. After 6 days, G418 was reduced to 0.5 
mg/ml.  G418 resistant clones were picked after two weeks and then expanded. Stable expression 





3.9. Native PAGE, SDS PAGE and western blot 
Cells were lysed with RIPA buffer containing a protease inhibitor, centrifuged, and supernatant 
was used. BCA method was used for protein quantification (Pierce BCA protein assay kit, 
Waltham, MA).  SDS-PAGE and Western blot was performed as routine. For native PAGE, 10 
µg of protein was mixed with equal volume of 2× native sample buffer (Bio-Rad laboratories, 
Ltd, Hercules, CA), and were loaded onto 8% poly acryl amide gels without SDS. The 
electrophoresis was at 60V for 3.5-4 hour. Proteins were transferred to PVDF membrane for 
overnight at 4oC. Dilutions for primary antibodies were anti-α-tubulin, anti-HDAC6 anti-
vinculin, (1:1000, Cell Signaling Technology, Beverly, MA), anti-acetylated α-tubulin (1:5000), 
anti-Sirt-2 (1:500), anti-α-TAT (1:1000), anti-flag (1:1000) (Sigma Aldrich, St. Louis, MO). A 
goat anti-rabbit and anti-mouse polyclonal horseradish peroxidase conjugated secondary 
antibody (1:1000, Cell Signaling Technology, Beverly, MA) was used. Blots were established 
using a chemiluminescence detection kit (Pierce ECL western blotting substrate, Thermo 
Scientific, Rockford, IL). 
3.10. Analysis of CD44+CD24+EpCAM+ population in PANC-1 cells by flow cytometry 
PANC-1 cells in 60 x 15mm type cell culture dish were scrapped, washed with PBS, and then 
blocked with staining buffer  (DPBS that is supplemented with 0.2% (w/v) BSA, pH 7.4) for 10 
min. Cells were triple-stained with phycoerythrin (PE)-conjugated anti-CD24, PE-Cy7 
conjugated anti-CD44 and APC-conjugated anti-EpCAM antibodies (BD Biosciences, San Jose, 
CA)  for 20 min on ice and then samples were washed with staining buffer thrice. Cells stained 
with individual antibodies were used as compensation controls. Live cells were analyzed 
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immediately with flow cytometry by using DAPI stain. PE-Cy7+ and APC+ subpopulation in the 
PE+ gated cells indicated CD44+CD24+ EpCAM + subpopulation.  
 
3.11. Scratch assay 
Confluent pancreatic cancer cells in 6-well plate were wounded manually by scraping the 
monolayer using a p1250 sterile pipette tip. Cells were washed immediately with media to 
remove debris. After taking the zero-hour time point pictures, cells were treated with compounds 
as indicated in specific experiments. Cells were then incubated at 37oC in a humidified 5% CO2 
atmosphere. Wound closure was captured using an inverted microscope at 6, 12, 24, 30, 48 hrs 
under high-power field (100X magnification). The extent of wound closure was calculated as 
follows: (Distance of remaining wound gap × 100 ÷ Distance of original wound gap)-100 %. 
3.12. Tumor spheroid formation assay 
 Single cell suspension was plated into 24 well ultra-low attachment plates (Corning Inc., 
Corning, NY) at a density of 4,000 cells/well in stem cell media and incubated at 37°C in a 
humidified atmosphere of 95% air and 5% CO2. Stem cell media consist of, DMEM 
supplemented with 1X B27 Supplement, 20 ng/ml human basic fibroblast growth factor, 20 
ng/ml epidermal growth factor, 100 units/ml penicillin/streptomycin (Invitrogen, Grand Island, 
NY), and 4g/ml heparin calcium salt (Fisher Scientific, Pittsburg, PA). Primary spheroids were 
counted and collected after 10-14 days manually by looking under the microscope. Size of the 
spheroids was measured using Image J software. Primary spheroids were further trypsinized and 
then dissociated with 900 blunt end pipetting needles (VWR, Radnor, PA) and then reseeded into 
ultra-low attachment plates for the secondary spheroids. After 10-14 days secondary spheroid 





3.13. Fluorescence polarization assay and Alpha assay 
pTBSG-HuR and pTBSG-RRM1/2 plasmids encoding full-length human antigen R (HuR) and 
the RNA recognition motifs 1 and 2 (RRM1/2, residues G18-N186) of HuR, respectively, were 
constructed by KU COBRE-PSF Protein Purification Group. Musashi1 (MSi1) RNA oligo (5ʹ-
GCUUUUAUUUAUUUUG-3ʹ with 3 ʹ fluorescein or 3 ʹ biotin) was purchased from Dharmacon 
(Thermo Scientific, Lafayette, CO). RNAs were pretreated by heating at 95°C for 5 min and 
immediately cooling on ice for 5 min. 
For the fluorescence polarization assay, experiments were performed in 96-well black plates 
(Corning, Corning, NY) with a final volume of 100 µl using the BioTek Synergy H4 plate reader 
(Biotek, Winooski, VT). Twenty-five nM full-length human HuR and 2 nM fluorescein labeled 
Msi1 RNA oligo were used. Compounds with five doses (2 nM-20 µM) were added to the wells 
prior to the protein-RNA complex. Anisotropy measurements were taken after incubation at 
room temperature for 2 hr. IC50, the concentration causing 50% inhibition, was calculated via 
sigmoid fitting of dose response curve using Prism 5.0.  Ki was calculated using free online 
software (http://sw16.im.med.umich.edu/software/calc_ki/). 
For Alpha assay, experiments were performed in 96-well white 1/2 area plate (Perkin Elmer, 
Waltham, MA) with a final volume of 50 µl. Multiple doses of compounds were added to the 
wells first, followed by pre-formed RRM1/2-Msi1 complex (100 nM RRM1/2 protein and 25 nM 
Msi1 RNA), donor beads and acceptor beads (Perkin Elmer, 20 µg/ml final concentration). 
Measurements were taken after incubation at room temperature for 2 hr.  IC50 and Ki were 





3.14. Surface Plasmon Resonance assay 
The Surface Plasmon Resonance (SPR) experiments were performed using a BIACORE 3000 
(GE Healthcare) at 20°C and used to study the binding interaction of St-3 with either full length 
HuR or RRM1/2 of HuR.  The ligands, HuR, RRM1/2 were immobilized using the standard 
primary amine coupling reaction and followed by standard procedures. The sensor chip surface 
was initially activated with a 1:1 mixture of N-hydroxysuccinimide (NHS, 115 mg/ml) and N-(3-
dimethyl-aminopropyl)-N'-ethyl-carbodiimide-hydrochloride (EDC, 750 mg/ml) for 7 min each 
with a flow rate of 5 µl/min. Full-length HuR protein and RRM1/2 protein were then applied to 
the flow cells in 10 mM sodium acetate, pH 4.5, and immobilized to a density of 7200 RU and 
3800 RU (response units), respectively. An adjacent flow cell was left blank to serve as a 
reference surface. The activated carboxylic acid groups were quenched with a 7-minute injection 
of ethanolamine (1 M, pH 8.5). To collect kinetic binding data, compound St-3 in 20 mM 
HEPES pH7.4, 150 mM NaCl, 3 mM EDTA, 0.05% p20 (v/v), 5% DMSO (v/v), were injected 
over the flow cells at the indicated concentrations at a flow rate of 60 μl/min and at 20°C. The 
complex was allowed to associate for 4 min and dissociate for 3 min. Considerable care was 
taken to prevent contamination.  Samples were carefully injected to avoid carryover effects and 
the system was carefully washed before injection of each new sample. The sample flow rate was 
set at 60 μl/min to determine the kinetic and equilibrium constant. The equipment surfaces were 
washed extensively with buffer solution to restore the surfaces before each binding experiment. 
Data analysis was performed using BIA evaluation software. Data analysis and sensor grams 
were automatic corrected for nonspecific bulk refractive index effects. Standard procedures for 
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the 1:1 Langmuir binding fit model were used for the kinetic analysis of ligand binding to the 
protein. 
 
3.15. Data analysis  
Combination Index (CI) were calculated using the CompuSyn software. CI value > 1.1 indicates 
antagonism, CI value = 0.9-1.1 indicates additive effect, and CI value < 0.9 indicates synergism. 
Statistical analysis was performed using SYSTAT 11 software for student T-test. A difference 























Chapter 4. Mechanisms of High Dose Ascorbate Inhibiting Pancreatic Cancer 


















High-dose intravenous ascorbate (IVC) bypasses bioavailability barriers of oral ingestion and 
provides pharmacologic concentrations in tissues, exhibiting pro-oxidant anti-cancer activities. 
In pancreatic cancer pre-clinical models, pharmacologic concentrations of ascorbate has been 
shown to sensitize the tumor to the 1st line chemotherapeutic drug gemcitabine. In an orthotopic 
mouse tumor model, ascorbate treatment alone decreased pancreatic cancer growth and 
metastasis.  Ascorbate treatment resulted in EMT inhibition, as evidenced by enhanced 
expressions of epithelial markers and suppressed expression of mesenchymal markers in both 
tumor samples as well as in pancreatic cancer cell lines. Ascorbate treatment influenced the 
tumor micro environment by decreasing the expression and activity of MMP-2, promoting 
collagen synthesis and enhancing stromal desmoplastic reaction. Furthermore, ascorbate 
decreased expression of HDAC6 and activity of silent information regulator-2 (Sirt-2), which are 
known EMT inducers.  As a result of HDAC6 and Sirt-2 inhibition, ascorbate robustly increased 
α-tubulin acetylation in pancreatic cancer cells. Acetylation promoted tubulin polymerization and 
stabilization, resulted in inhibition of cell motility and mitosis. An effect mimics the cellular 
outcome of paclitaxel. Taken together, pharmacological concentrations of ascorbate inhibited 
pancreatic cancer cell EMT and affected the tumor microenvironment, led to inhibition of tumor 






Vitamin C (ascorbic acid, with its sodium salt named ascorbate) is an essential micronutrient to 
human beings. It is required for many enzymatic reactions catalyzed by Fe+2-2-oxoglutarate 
dependent dioxygenases (Collagen prolyl-3-hydroxylase, prolyl-4-hydroxylase, dopamine β-
hydroxylase, HIF-α hydroxylase, histone demethylases containing jumonji catalytic domain, 
etc.). Ascorbate maintains iron in ferrous state in these enzymes, thereby maintaining full activity 
of this class of enzymes (251-258). 
Ascorbate has long been used in complementary and alternative medicine for treatment of 
cancer.  Early hypothesis includes that ascorbate inhibited the enzyme hyaluronidase, which 
otherwise destroyed collagen so that cancers could metastasize (259). Cameron and the Nobel Prize 
laureate Pauling advocated the use of high-dose ascorbic acid (10 gms/day intravenous 
administration for up to 10days followed by 10gms/day orally indefinitely) to treat cancer. Use 
of such high doses improved quality of life, and prolonged survival time in terminal oncologic 
patients, and even resulted in complete tumor regression in a few cases (260, 261). However, two 
carefully designed double-blind trials using oral ascorbate carried out at Mayo Clinic showed no 
significant differences between ascorbate and placebo group with regard to survival time (262). 
Now it is known that intravenous administration of Vitamin C (IVC) achieves high systematic 
concentrations in milli-molar range that could not be achieved by oral ingestion. IVC bypasses 
the physiological “tight control” mechanisms that limit its systematic concentrations with oral 
ingestion, such as intestinal absorption, tissue accumulation, renal reabsorption and excretion, 
and achieves pharmacological concentrations (263-265). The pharmacologic concentrations of 
ascorbate generate ascorbate radical and H2O2 which induce oxidative damages selectively to 
tumor cells (266-269). Many laboratories have shown in rodent xenograft experiments that 
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ascorbate decreased the growth rate of various aggressive tumors, such as pancreatic cancer, 
glioblastoma, ovarian cancer, prostate cancer, hepatoma, colon cancer, sarcoma, leukemia, 
mesothelioma, breast cancer, and neuroblastoma (267-274). 
Recently, considerable interest has been raised concerning using high dose intravenous vitamin 
C (IVC) as adjuvant therapy to standard chemotherapies (266).  IVC is safe and free of common 
toxic side effects that often accompany chemotherapies. A phase 1 trial by Hoffer et al (275) 
with 24 terminal cancer patients found IVC of 1.5 g/kg 3x weekly was free of significant 
toxicity, and unexpectedly, 2 patients had stable disease. Our group reported a pilot trial in stage 
III-IV ovarian cancer patients (266) with participants randomized to the standard 
paclitaxel/carboplatin therapy or the standard chemotherapy plus IVC (75-100 g/ infusion, 2 x 
weekly for 1 year). IVC treatment substantially decreased chemo-associated toxicities (266). The 
median time for disease progress/relapse was prolonged for 8.75 months in the ascorbate + 
chemo group than the chemo-only group, despite that the trial was not statistically powered to 
detect efficacy (266). Two trials in pancreatic cancer patients were recently reported by Monti et 
al (276) and Cullen et al (277), both using IVC (50-100 g/infusion 2-3x weekly) together with 
gemcitabine or gemcitabine plus the EGFR inhibitor, erlotinib. In both trials, IVC did not 
increase any toxicity to the chemotherapy. In Monti’s trial, 7 out of 9 patients had tumor 
shrinkages after only 8 weeks of treatment (276). In Cullen’s trial, potential in prolongation of 
survival was shown compared to historical controls (277). Therefore, IVC has emerged to be a 
promising adjuvant treatment for pancreatic cancer with clinical benefit in low toxicity and 
potential improvement in efficacy. 
Our previous study using a panel of 7 pancreatic cancer cell lines showed that ascorbate 
sensitized pancreatic cancer cells to gemcitabine treatment (278). Ascorbate inhibited metastasis 
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in PANC-1 orthotopic model system.  Our recent studies have explored mechanisms of ascorbate 
mediated cell death in cancer cells (266). However, it is still an open question as to how 
ascorbate exerts its anti-metastatic property. A mounting body of literature suggests that EMT 
and tumor micro environment are both critically involved in the acquisition of metastatic 
potential.  Led by preliminary experimental observations, we aimed to investigate the 
mechanisms of ascorbate on regulation of EMT and tumor environment. 
4.3. Results 
4.3.1. Ascorbate decreased pancreatic cancer cell viability, invasion, migration, and 
metastasis. 
A panel of 8 human pancreatic cancer cell lines and 1 murine pancreatic cancer cell line were 
used to examine sensitivity to ascorbate treatment. These cell lines represent genotypes of 
mutations commonly found in human pancreatic cancers (Table 1). Cells were exposed to 0-20 
mM of ascorbate for 1-2 hrs, which are concentrations and time courses easily achievable 
clinically (267). Cell viability was detected 24 hrs after the treatment. Massive cell death was 
detected in all tested cancer cell lines, even below 5 mM ascorbate (Fig. 4.1A). In contrast, the 
treatment of 20 mM ascorbate only minimally influenced viability of a non-tumorigenic 
pancreatic ductal epithelial cell hTERT-HPEN, fibroblasts (WI-38) and normal lymphocytes. 
Addition of catalase, an enzyme that specifically degrades H2O2, completely reversed ascorbate -
induced cell death in cancer cells, consistent with previous studies indicating that H2O2 was the 
effective molecule when pharmacologic ascorbate was present (268, 269). Immunohistochemical 
analysis on tumor samples showed that proliferating cell nuclear antigen (PCNA), an indicator of 
cell proliferation, decreased remarkably in tumors treated with ascorbate (Fig. 4.1B). Mitosis 




























Figure 4.1- Ascorbate inhibited pancreatic cancer cell growth in vitro and in vivo  A. 
Sensitivity of pancreatic cancer cells and normal cells to ascorbate. Cells were exposed to 0-
20 mM ascorbate for 1-2 hrs. Cell viability was detected at 24 hrs post treatment by MTT 
assays. +cat,  pre-incubation with 600 U/ml catalase. Data represents Mean ± SD of 3 
experiments each done in triplicates. B. Immunohistochemical analysis of proliferating cell 
nuclear antigen (PCNA) with formalin fixed tumor samples. Bar graph (right) represents the 
average number of PCNA positive cells per field. 15 fields from 3 different tumors from each 
group were analyzed. **, P<0.001 by T-test. C. Histological analysis of mitosis on H&E 
stained tumor slides. Bar graph (right) shows mitotic index, which was average number of 














































(Fig. 4.1C).   Interestingly, at a sub-cytotoxic concentration of 1 mM, ascorbate was able to 
inhibit PANC-1 cell migration and invasion through matrigel gel coated Boyden chambers, 
without influencing viability of the cells (Fig. 4.2A, B, and C). We further investigated the 
effects of ascorbate in vivo by using orthotopic pancreatic cancer model in mouse. Luciferase 
expressing PANC-1 cells were orthotopically injected into the pancreas of nude mice. After the 
tumors were formed, mice were treated with intraperitoneal doses of ascorbate at 4 g /Kg body 
weight/day for 45 days (equivalent to 1.3 g/Kg/day by intravenous injection) (268).  
Cell line K-Ras P53 CDKN2A/p16 SMAD4/DPC4 
BxPC-3 WT 220 Cys WT HD 
AsPC-1 12 Asp 135 Δ1 bp WT WT 
MIA PaCa2 12 Cys 248 Trp HD WT 
Su86.86 12 Asp 245 Ser HD WT 








Intron 2 splice 
site 
HD 
PANC-1 12 Asp 273 His, 273 Cys HD WT 
Table -1 Genotype of the pancreatic cancer cell lines used, showing the most 
common mutations in pancreatic cancer (7). 
WT—wild type, Δ—deletion, bp—base pair, HD—homozygous deletion, Mut225-
282— mutations found between codons 225-282 
 





































Figure 4.2- Ascorbate inhibited 
pancreatic cancer cell invasion and 
migration in vitro  A. Matrigel invasion 
assays for pancreatic cancer cell 
migration and invasion. PANC-1 cells 
were exposed to a sublethal dose of 
ascorbate (1 mM). Cell migration 
(without Matrigel) and invasion (with 
Matrigel) were detected at 24hrs. B. Bar 
graph shows the average number of 
migrated/invaded cells per field. Data 
represents ≥3 experiments each done in 
triplicates. C. Ascorbate 1mM treatment 
for 24hrs had a little impact on cell 
viability of PANC-1 cells. *, P<0.05, **, 

























































Figure -4.3B Figure -4.3C 
Figure -4.3D Figure -4.3E 
Figure 4.3- Ascorbate inhibited pancreatic cancer growth and metastasis in vivo.  A. 
Representative bioluminescence images of mice bearing orthotopic pancreatic 
xenografts with and without ascorbate treatment at indicated days. Day 0 indicated the 
beginning of treatment, which was 2 weeks post orthotopic injection of luciferase 
expressing PANC-1-Leu cells into mouse pancreas. Day 45 was the end of the 
experiment. Asc, ascorbate treatment (n=8) at intraperitoneal dose of 4 g/kg/day. Control 
(Ctrl) mice (n=8) were treated with saline that had the same osmolarity as the ascorbate 
injections. B. Total tumor burden per mouse by imaging was quantified as 
photons/sec/cm2/sr.  *, P<0.05 by T-test. Total tumor weight (C), number of metastatic 
lesions in each mouse (D) and percentage of mice that had metastasis (E) were 




Live animal tumor imaging showed that ascorbate treatment significantly reduced tumor 
progress longitudinally (Fig. 4.3A, B). Number of mice with metastasis decreased (Fig. 4.3E), 
and number of metastatic lesions in each mouse were significantly decreased in the ascorbate 
group (Fig. 4.3D). At the end of the experiment, mice were euthanized and total tumor weight 
was measured. A significant decrease in average tumor weight was found with ascorbate 
treatment (Fig. 4.3C).  
4.3.2. Ascorbate influenced pancreatic cancer cell EMT, inhibited MMPs, and increased 
collagen content and desmoplasia in tumor stroma.  
We have published previously that the oxidative action of high ascorbate concentrations could 
directly induce cancer cell death (266). Here, our data showed that even at sub-cytotoxic 
concentrations, ascorbate (1 mM) decreased PANC-1 cell invasion and metastasis (Fig. 4.2 A, B, 
and C). To investigate the mechanisms involved, markers in pancreatic cancer EMT were 
examined, because EMT has been suggested to be the initial step for the complicated process of 
cancer cell dissemination and metastasis (5). Loss of E-cadherin, a cell surface protein, is the 
hallmark of EMT (279). In pancreatic cancer cells treated with ascorbate, E-cadherin expression 
was enhanced at both mRNA level (Fig. 4.4A) and protein level (Fig. 4.4B). Consistently, Snail, 
the E-cadherin repressor, was inhibited (Fig. 4.4A, 4.4B). The mesenchymal marker vimentin 
was decreased at both mRNA and protein levels (Fig. 4.4A, B). Other markers of EMT also 
showed a pattern supporting the inhibition of EMT, which meant increase in epithelial markers 
and decrease in mesenchymal markers with ascorbate treatment (Fig. 4.4A-C). Decrease of Snail 
was confirmed in mouse tumors treated with ascorbate (Fig. 4.4C). Moreover, the epithelial 
molecule CK-19 showed a robust increase in tumor samples from ascorbate-treated mice (Fig. 
4.4C). As EMT is highly associated with CSC, we examined the effect of ascorbate on 
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pancreatic CSCs. Indeed, spheroids formation assays showed that ascorbate of 2.5 mM reduced 
the number of tumor spheroids in both PANC-1 and BxPC-3 cells (Fig. 4.4D).  
Remarkably, mRNA of collagens was greatly increased in ascorbate treated pancreatic cancer 
cells in vitro (Fig. 4.4A), accordingly collagen content was increased in tumor stroma of 
ascorbate treated mice (Fig. 4.5A). Desmoplasia in tumor stroma was significantly enhanced in 
ascorbate treated mice (Fig. 4.5B). These changes in the tumor microenvironment may 
contribute to the reduction of invasiveness of the tumor (280).  In contrast, no such increase in 
collagen or fibrosis was observed in the livers of the ascorbate treated mice (Fig. 4.5C).    
Ascorbate decreased mRNA levels of multiple MMPs (Fig. 4.4A). We particularly examined 
MMP-2 expression and activity, because MMP-2 was suggested to be important in pancreatic 
cancer cell invasion (281). Ascorbate treatment decreased MMP-2 expression in a dose-
dependent manner in pancreatic cancer cells (Fig. 4.6A). Activity of secreted MMP-2 was 
determined using gelatin zymography assay. Significant decrease was found in gelatinolytic 
activity of MMP-2 in the supernatant media of PANC-1 cells treated with ascorbate (Fig. 4.6B).   
4.3.3. Ascorbate enhanced α-tubulin acetylation and increased tubulin polymerization  
In addition to the EMT inhibition and changes in tumor microenvironment, robust α-tubulin 
acetylation was found in PANC-1 and BxPC-3 pancreatic cancer cells and the acetylation was 
dose dependent to ascorbate treatment (Fig. 4.7A).  At the same concentration, ascorbate only 
minimally increased α-tubulin acetylation in the immortalized pancreatic ductal epithelial cell 
hTERT-HPEN. Treatment with H2O2 mimicked the effects of ascorbate, whereas catalase 
completely eradicated α-tubulin acetylation induced by ascorbate (Fig. 4.7B), reconfirming that 



















Figure 4.4- Ascorbate affected pancreatic cancer EMT markers. A. qRT-PCR for changes 
in EMT markers. PANC-1 cells were treated with 2.5 mM ascorbate. Data represent Mean ± 
SD of 2-6 independent experiments.  B. Western blot in PANC-1 cells showing expression of 
E-cadherin (E-Cad), vimentin (Vim) and Snail after ascorbate treatment. Vinculin was a 
loading control. C. Western blot in mouse tumor samples from ascorbate treated and saline 
treated (Control) mice showing changes in CK-19 and Snail. D. CSCs population was 






































































Figure 4.5- Ascorbate increased collagen content and desmoplasia in tumor stroma.   
A. Histological analysis of tumor samples for collagen. Formalin fixed tumor samples were 
sliced and subjected to Masson’s trichrome staining. Collagen was stained blue, while 
cytoplasm was stained pink. Bar graph representing the average of % area collagen/cross 
section. 15 fields from 3 different tumors from each group were analyzed. B. Histological 
analysis of desmoplasia on H&E stained tumor slides. Bar graph shows desmoplasia, which 
was represented as % of area contains desmoplastic response. Tumors from 4 mice in each 
group were examined. C. Masson’s trichrome staining for collagen and fibrosis of livers 
from control and ascorbate treated mice. *, P<0.05, **, P<0.001 by T-test. 

















































(assembly and disassembly) is important for general cellular functions such as cell division, 
intracellular trafficking, and ciliary beating (282). Acetylated α-tubulin is associated with stable 
microtubules (283). Overstabilized microtubules could result in malfunction of cell division and 
movement (283). The chemotherapeutic drug paclitaxel works to bind and stabilize 
microtubules. Here, we found overstabilization of microtubules induced by ascorbate treatment.  
Four hours after ascorbate treatment, there was an enrichment of high molecular weight fractions 
of acetylated α-tubulin, indicating microtubule polymerization, mimicking the effect of 
paclitaxel (Fig. 4.8). As cold temperature is known to induce depolymerization of tubulin, cell 
lysates were put on ice (4°C) and the ascorbate-induced tubulin polymerization was found stable 
over time at either 37 °C or 4 °C (Fig. 4.9). The degree of α-tubulin acetylation was inversely 
correlated to the viability of pancreatic cancer cells after ascorbate treatment (BxPC-3, r = -
0.88609, PANC-1, r = -0.98287 by Pears test) (Fig. 4.12A, B). These results were consistent 
Figure -4.6A Figure -4.6B 
Figure 4.6- Ascorbate affected MMP-2 expression and activity.  A. qRT-PCR for MMP-2 
mRNA expression in PANC-1 cells treated with ascorbate.  B.  Gelatin zymography assay for 
MMP-2 enzymatic activity after ascorbate treatment. Supernatant media was used for 
detection of MMP-2 activity using gelatin zymography. Data represents Mean ± SEM of 3 


























































with the mitosis and metastasis inhibition we found in tumors from ascorbate-treated mice (Fig. 
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Figure -4.7A 
Figure -4.7B 
Figure 4.7-Ascorbate promoted α-tubulin acetylation. A. Western blot analysis of acetylated 
α-tubulin in pancreatic cancer cells (BxPC-3 and PANC-1), and an immortalized non-cancerous 
pancreatic epithelial cell line hTERT-HPNE. Cells were treated with 0, 1.25, 2.5 mM ascorbate 
for 4 hrs. B.  Immunofluorescence showing acetylated α-tubulin in cells after ascorbate 2.5 mM 
and H2O2 500 µM for 4 hrs. Ascorbate +Cat, co-treatment of ascorbate and 600 U/ml catalase for 
























































Figure 4.8- Ascorbate promoted tubulin polymerization. Tubulin Polymerization was 
detected by native PAGE. After 4hrs of ascorbate or paclitaxel treatment, cells were lysed 
in RIPA buffer. For native PAGE 10 µg cytosolic fraction was loaded in β-mercaptoethanol 
free buffer without boiling and the electrophoresis was performed on 8% poly acryl amide 
gel. α-tubulin acetylation was confirmed by SDS PAGE and western blot as shown in the 


















4.3.4. Ascorbate enhanced α-tubulin acetylation through inhibition of Sirt-2 and HDAC6 
Alpha-tubulin acetylation is under the balanced control of enzymatic activities of acetyl 
transferase (alpha tubulin acetyltransferase(α-TAT)) and deacetylases (Sirt-2 and HDAC6) 
(282). In both PANC-1 and BxPC-3 cells (Fig. 4.10A), and in tumors from ascorbate treated 
mice (Fig. 4.10B), ascorbate decreased protein levels of HDAC6. No change in Sirt-2 protein 
Figure -4.9 
Figure 4.9-Ascorbate stabilized microtubule polymers. Cold induced microtubule 
depolymerization assay in PANC-1 and BxPC-3 pancreatic cancer cells. After 
ascorbate treatment for 4hrs cell lysates were exposed to either 370C or sit on ice (4 
0C). At indicated time points, samples were analyzed by native PAGE analysis for Ac-




levels was detected either in cell lines or in tumor samples (Fig. 4.10A, B). No change in α-TAT 
expression observed in PANC-1 and BxPC-3 cells after ascorbate treatment (Fig. 4.10A).  
To examine whether HDAC6 plays a role in ascorbate-mediated α-tubulin acetylation, we first 
overexpressed HDAC6 in PANC-1 cells using a Flag-tagged HDAC-6 plasmid (pcDNA3.1 + 
HDAC6-Flag) (Fig. 4.10C). The overexpression only partially counteracted with ascorbate and 
partially decreased the level of α-tubulin acetylation caused by ascorbate (Fig. 4.10C). We 
further inhibited HDAC6 activity by using an HDAC inhibitor trichostatin A (TSA). TSA 
markedly enhanced α-tubulin acetylation in both PANC-1 and BxPC-3 cells, despite the fact that 
the two cell lines had different sensitivity to the treatment (Fig. 4.13A). Co-treatment of 
ascorbate and TSA were evaluated against cell viability. Results showed additive to synergistic 
effect in inducing PANC-1 and BxPC3 cell death, as shown by the “heat map” of cell viability 
and the combination indices (CIs) (Fig. 4.13B).  These data indicated that by manipulating 
activity of HDACs, ascorbate induced α-tubulin acetylation and cell viability were affected. 
Activity of enzymes can be inhibited at either expression level or enzyme activity level. 
Although there was no change in protein levels of Sirt-2 after ascorbate treatment, we found a 
decreased NAD+ levels in pancreatic cancer cells treated with ascorbate (Fig. 4.11A). Because 
NAD+ is an essential co-factor for Sirt-2 activity (284), ascorbate may affect Sirt-2 deacetalyzing 
activity even though Sirt-2 protein levels were not changed.  To investigate this possibility, 
NAD+ was supplemented to the cell culture media. With 2 mM of NAD+ added to the culture 
media, intracellular NAD+ was partially rescued (Fig. 4.11A), and ascorbate mediated α-tubulin 
acetylation was partially reversed (Fig. 4.11B). A more complete rescue of NAD+ by adding 8 
mM (Fig. 4.11A), almost completely reversed ascorbate mediated α-tubulin acetylation (Fig. 






















Figure 4.10- Ascorbate decreased expression of HDAC6 to regulate α-tubulin 
acetylation. A. Western blot analysis for Sirt-2, HDAC6 and α-TAT. PANC-1 and 
BxPC-3 cells were treated with ascorbate for 4 hrs. Vinculin was a loading control. B. 
Western blot analysis of tumor samples from control and ascorbate treated mice, probed 
for HDAC6, Sirt-2, and vinculin antibodies. Bar graph (right) represents the average 
Sirt-2/vinculin and HDAC-6/vinculin band intensities in the tumor samples (n=5). Data 
represents Mean ± SEM. C. Overexpression of Flag tagged HDAC6 in PANC-1 cells 






































Figure 4.11-Ascorbate regulates Sirt-2 activity by depleting NAD+ levels.  A. 
NAD+ levels in PANC-1 cells with ascorbate treatment (5 mM, 4 hrs) and NAD+ 
supplementation (8 mM, 6 hrs prior to ascorbate treatment). B. Western blot for α-





















Figure 4.12- NAD+ supplementation 
rescued cell death induced by ascorbate 
A, B. Correlation between tubulin 
acetylation and cell death induced by 
ascorbate. C.NAD+ supplementation 
rescued cell death induced by ascorbate. *, 























Figure 4.13 - Combination effect of ascorbate and TSA on cell viability. A. 
Combination effect of ascorbate and HDAC inhibitor, TSA on α-tubulin acetylation. 
PANC-1 and BxPC-3 cells were exposed to ascorbate and TSA, or combinations of 
ascorbate and TSA for 4 hours.  B. Combination effect of ascorbate and TSA on cell 
viability. PANC-1 cells were exposed to ascorbate and TSA, or combinations of ascorbate 
and TSA for 48 hours. Cell viability was measured using MTT assay. Combination Index 






High-dose ascorbate had been proposed as cancer treatment by Linus Pauling and Ewan 
Cameron (260, 261), but was discarded as cancer therapy after two formal clinical trials showed 
negative results using oral ascorbate (262, 285). Later on, pharmacokinetic studies revealed that 
oral ascorbate could not provide concentrations high enough to induce cancer cell death. Instead, 
intravenous administration delivered millimolar concentrations of ascorbate into tissues which 
then generated H2O2 to induce death in cancer cells (264, 267-269). Following this rationale, 
many animal studies showed tumor inhibitory effects of high-dose parenteral ascorbate in 
various types of cancers, either as a single agent, or used in combination with chemotherapeutic 
drugs and radiation (267, 270-274, 286-289). Previously, our studies found that ascorbate had 
synergistic effects with the 1st line chemotherapeutic drug gemcitabine in inhibiting growth of 7 
different pancreatic cancer cell lines (278). In the current study, our data further demonstrated 
that ascorbate inhibited cancer cell EMT and reinforced tumor microenvironment by enhancing 
collagen synthesis to inhibit metastasis of this aggressive tumor.  
Lack of successful chemotherapy is partly due to heterogeneity of pancreatic tumors. 
Heterogeneity led to differential sensitivity of neoplastic cells to chemotherapeutic drugs leading 
to tumor recurrence (290). A small molecule compound that has a broad range of anti-tumor 
activity against a heterogeneous population of pancreatic cancer cells would be an ideal tool for 
treatment. High dose ascorbate has the potential to be such a tool, as it induces cell death in 
several different pancreatic cancer cell lines that are quite different in terms of their genomic 
landscape (Table 1). This suggests that ascorbate can be a potent therapeutic option for 
pancreatic cancer patients. 
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Some progress has been made in understanding the mechanism of selective toxicity to cancer 
cells. In previous studies, we demonstrated that pharmacologic ascorbate generated H2O2, 
induced DNA damage and ATP depletion and subsequently triggered a series of cellular 
responses including activation of ATM/AMPK and inhibition of mTOR, which could link to 
cellular outcomes such as inhibition of proliferation, cell cycle arrest, apoptosis, necrosis and 
autophagy (266). Known as the Warburg Effect (291), ATP production in cancer cells relies 
primarily on glycolysis (291-293). Since glycolysis is a much less efficient way for ATP 
production compared to oxidative phosphorylation that is primarily used by normal cells, cancer 
cells could be more sensitive to ascorbate -induced metabolic stress than normal cells. Our data 
here showed decrease of NAD+ in pancreatic cancer cells treated with ascorbate, further 
supporting this hypothesis. Both DNA repair and ATP production require NAD+, therefore 
ascorbate induced stress can be catastrophic to cancer cells.  
Moreover, data here showed that depletion of NAD+ influenced the activity of a cytosolic 
deacetylase Sirt-2. Together with inhibition in the cytosolic histone deacetylase HDAC6, 
ascorbate treatment caused robust increase in α-tubulin acetylation. Acetylation of α-tubulin 
enhanced the stability of polymerized tubulin and thus interrupted the dynamics of microtubules. 
The dynamics of microtubules is important in intracellular transport, cell migration and division. 
Inhibition of microtubule dynamics effectively impairs cell motility and mitosis (294). An 
example is the chemotherapeutic drug Paclitaxel (295). Here, we found ascorbate induced α-
tubulin acetylation resulted in overstabilized tubulin polymerization and subsequent reduction in 
mitosis and cell invasiveness.    
Microtubule dynamics was also found to control cell-basement membrane interaction in the 
process of EMT (296).  In this study, we found ascorbate inhibited parameters of cancer cell 
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EMT and influenced cell-stroma interaction. MMPs responsible for cancer cell dissemination 
were inhibited. In the ascorbate -treated tumor stroma, collagen levels and desmoplasia 
significantly increased. Stiffness of tumor tissues greatly increased. Increased tissue 
concentration of ascorbate could enhance collagen biosynthesis, as ascorbate is an essential 
cofactor for prolyl and lysyl hydroxylases in collagen biosynthesis (297). Increased collagen 
level strengthened the extra cellular matrix, which formed a stronger barrier for tumor cells to 
metastasize. The increased desmoplasia or fibrosis has been thought to be a host defense 
mechanism, similar to scar formation at healing wounds, probably to impede the invasion of 
carcinoma (298, 299). The function of desmoplastic tumor stroma however was thought to be 
dynamic during cancer progression, with a tumor-promoting role suggested by some studies 
(300, 301). However, a recent study convincingly demonstrated that reduction of collagen 
content in pancreatic cancer by depletion of alpha smooth muscle actin positive (αSMA+) 
myofibroblasts resulted in invasive tumor progress and poor survival (280). This indicates that 
fibrosis and desmoplasia in pancreatic cancer stroma constituted a protective response from the 
host. It is not known whether ascorbate affects the αSMA+ myofibroblasts in pancreatic tumors. 
Apparently, the ascorbate -induced fibrosis is specific to tumor tissues because liver pathology 
showed normal results without fibrosis. While the detailed tumor-stroma interaction under 
ascorbate treatment is worth further investigation, an inhibitory effect was seen in metastasis in 
ascorbate -treated tumors.   
The vast majority of pancreatic cancer patients have metastatic disease at the time of diagnosis, 
leading to dismal prognosis and poor treatment outcomes. As there are few options in the 
management of this devastating cancer, the low-toxic therapy of high-dose intravenous ascorbate 
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holds great promise. As our mechanistic understanding advances, clinical study should be 













































Inhibition of HDACs results in growth arrest, differentiation, and apoptosis of tumor cell and 
causes tumor regression in animal models, thereby promoting HDAC inhibitors as promising 
agents for anti-cancer therapy. SAHA, an HDAC inhibitor, has been approved by the FDA for 
cutaneous T-cell lymphomas (CTCL) treatment. SAHA and another HDAC inhibitor MS-275 are 
in the pipeline for clinical development in the treatment of solid tumors. However, data from 
clinical trials showed no significant efficacy using current HDAC inhibitors in treatment of solid 
malignancies (302).  In order to increase efficacy, we tested a number of novel SAHA and MS-
275 derivatives. Compound St-1 showed lower IC-50 values compared to the parent compounds 
SAHA and MS-275 against pancreatic cancer cell lines (PANC-1, and BxPC-3). Neither the 
parent compounds nor St-1 were toxic to immortalized non-tumorigenic pancreatic ductal 
epithelial cells (hTERT-HPNE). St-1 is more potent in inhibiting CSCs when compared to the 
parent compounds. Collectively, the above findings suggest that St-1 could be a more potent 
anti-cancer compound compared to SAHA and MS-275.  
Surprisingly, we discovered another derivative St-3 which showed a totally different mechanism 
of action than the parent HDACs.  St-3 potently inhibited pancreatic CSCs, cell invasion and 
migration and induced cytotoxicity. Unlike the parent compounds, St-3 showed poor potency in 
HDAC inhibition. Using fluorescence polarization assay and amplified luminescent proximity 
homogeneous assay, we identified that St-3 is an inhibitor for HuR, a RNA binding protein.  
In this chapter, data will be described in two parts.   The first part will focus on findings of the 




5.2. Part 1: St-1 as a potent HDAC inhibitor 
5.2.1. Introduction 
Recent studies suggested that HDACs are involved in EMT regulation. Von Burstin and 
colleagues demonstrated that HDAC1 and 2 together with Snail, epigenetically silenced E-
cadherin expression, thereby induced EMT (303).  In another study, inhibition of HDAC6 using 
SiRNA or a small-molecule inhibitor, tubacin, attenuated TGF-β mediated EMT induction (304).  
Therefore, inhibition of HDACs is an attractive strategy to inhibit EMT.  
In this study, we focused on analogues of two major HDAC inhibitors, SAHA and MS-275, 
which are currently at different stages of clinical development for treatment of solid tumors. 
SAHA is a hydroxamic acid derivative that has been shown to inhibit Class1, 2, and 4 HDACs 
nonspecifically and was approved by FDA for CTCL treatment. However, SAHA showed only 
modest to no activity against breast, colorectal, non-small cell lung cancer (305) and squamous 
cell carcinoma of the head and neck (306) in clinical trial. The most common adverse effects of 
SAHA include diarrhea, fatigue, nausea, pulmonary embolism and thrombocytopenia. MS-275 is 
a synthetic benzamide derivative that inhibits HDAC1, 2 and 3. MS-275 enhances histone (H3 
and H4) acetylation, p21 expression and caspase-3 activation in peripheral-blood mononuclear 
cells and therefore has been tested in phase 1 and 2 clinical trials to treat patients with leukemia 
and lymphoma as well as some solid tumors in phase 1 and 2 clinical trials (213, 216, 307). 
However, despite having a long half-life in humans (39-80 hrs) (307) it had limited antitumor 
activity in phase 1 clinical trials (216, 308). In pancreatic cancer patients, MS-275 had not shown 
objective response in a phase 1 study (213). Dose limiting toxicity of MS-275 includes 
infections, neurological toxicity and somnolence (201).  Current HDAC inhibitors in 
combination with other chemotherapeutic drugs also have not provided any additional 
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therapeutic benefits in clinical studies (214, 215). New HDAC inhibitors with better potency and 
specificity are needed. 
In an effort to look for more potent HDAC inhibitors, we tested 28 novel synthetic derivatives 
based on SAHA and MS-275 structures for their anti-cancer activity in vitro. 
5.2.2 Results 
5.2.2.1. Derivatives of SAHA and MS-275 inhibited pancreatic cancer cell proliferation 
First, we compared the anti-proliferative activity of the 28 derivatives to SAHA and MS-275 
against pancreatic cancer cell line PANC-1 and BxPC-3. Out of the 28 derivatives, compound St-
1 showed lower IC-50 (concentration that is required to kill 50% of the cells) values compared to 
both of the parent compounds (Fig. 5.1A, B). In PANC-1 cells, IC-50 values of SAHA and MS-
275 were both > 40 µM, while IC-50 of St-1 was 10.66 µM. In BxPC-3 cells, IC-50 was > 50 
µM for MS-275, 16 µM for SAHA, and 6.5 µM for St-1 (Table 2).   
We have also used the immortalized non-tumorigenic pancreatic ductal epithelial cells (hTERT-
HPNE) to examine toxicity of these compounds against normal cells in vitro.   Results showed 
that neither the parent compounds nor St-1 were toxic to hTERT-HPNE cells (Fig. 5.1C). St-1 
might possess low in vivo toxicity, which is worth further investigation, given its improved 
cytotoxicity to pancreatic cancer cells.  
5.2.2.2. St-1 potently induced apoptosis in pancreatic cancer cells  
Because various HDAC inhibitors have been shown to induce apoptosis, we examined the ability 
of St-1 in cleaving caspase-3, a major mediator of apoptosis. PANC-1 and BxPC-3 cells were 
exposed to different concentrations of SAHA, MS-275 or St-1. As shown in the figure (Fig. 5.2), 
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SAHA and MS-275 only weakly induced caspase-3 cleavage in 24 hrs of treatment. However, 























Figure 5.1- Cytotoxicity of SAHA, MS-275, 
and St-1 on pancreatic cancer cell lines. 
Pancreatic cancer cell lines PANC-1 (A), 
BxPC-3 (B), and hTERT-HPNE cells (C) were 
treated with increasing concentrations of 
SAHA, MS-275, St-1. Cell viability was 
measured by MTT assay after 48hrs for PANC-
1 and hTERT-HPNE cells, and after 24 hrs for 
BxPC-3 cells.*, P<0.05 versus MS-275; #, 
P<0.05 versus SAHA treatmentby T-test. 
Table -2 
Table 2- IC-50 values of SAHA, 
MS-275, and St-1.  




















5.2.2.3. St-1 inhibited pancreatic CSCs 
CSCs form spheroids in suspension culture by overcoming anoikis, a form of cell death caused 
by loss of adhesion. SAHA has been shown to induce morphological differentiation of PANC-1 
cells (309), implying its ability to reduce the undifferentiated CSCs. Hence, we tested the effect 
of SAHA, MS-275 and St-1 on CSCs, using sphere formation of pancreatic cancer cells. PANC-
1 cells were exposed to 10 µM, whereas BxPC-3 cells were exposed to 3 µM of SAHA, MS-275 
and St-1 and spheroids were allow to form for 7 days. The results showed that SAHA and MS-
275 at the concentration of 10 µM did not inhibit PANC-1 spheroid formation. St-1 under the 
Figure -5.2 
Figure 5.2-Effect of SAHA, MS-275 and St-1 on caspage-3 cleavage. PANC-1 and BxPC-3 
cells were treated with various concentrations of SAHA, MS-275 and St-1 for 24hrs and then 




same condition significantly reduced both number and size of PANC-1 spheroids. In BxPC-3 
cells, St-1 was more potent than SAHA in inhibiting the spheroid formation, while MS-275 did 
not show any effect at 3 µM (Fig. 5.3). The data indicated a stronger effect of St-1 in inhibiting 











5.2.2.4. St-1 increased histone acetylation 
We then examined the activity of St-1 in inhibiting HDACs. Acetylation in all 4 histones H2A 
(Lys 5), H2B (Lys 5), H3 (Lys 9) and H4 (Lys 8) was detected. Western blot analysis for histone 
Figure 5.3- St-1 inhibits PANC-1 and BxPC3 spheroids formation. Cells were 
seeded at 4000 cells/well in single-cell suspension into 24-well ultra-low adherent 
tissue culture plates. PANC-1 was treated with 10 µM, and BxPC3 was treated with 3 
µM of SAHA, MS-275 or St-3.  Spheroids were counted after 7 days.*, P<0.05, **, 

















































acetylation was performed with total lysate from PANC-1 and BxPC-3 cells after treatment with 



















Figure 5.4- Effect of SAHA, MS-275, St-1on acetylation of histones. PANC-1(A) and 
BxPC-3 (B) cells were exposed to SAHA, MS-275, St-1 or vehicle control for 24 hrs 






As expected, SAHA and MS-275 potently increased the acetylation of all 4 histones (H2A, H2B, 
H3, and H4) in both cell lines. St-1 increased histone acetylation similar to SAHA and MS-275. 
In addition to histones, HDAC inhibitors increased acetylation of many non-histone proteins 
such as α-tubulin and p53. SAHA and St-1 induced tubulin acetylation, whereas MS-275 did not.  
Inhibition in class I and II HDACs in theory could result in EMT inhibition by elevating E-
cadherin expression. Therefore, we determined whether St-1 could inhibit EMT. Indeed, all three 
HDAC inhibitors increased E-cadherin expression in PANC-1 and BxPC-3 cells, indicating EMT 
inhibition. 
5.2.3. Discussion 
Epigenetic changes are associated with malignant cellular transformation. Unlike genetic 
changes, epigenetic changes are reversible, raising the potential for altering epigenetic changes, 
using HDAC inhibitors, as cancer therapy. Several HDAC inhibitors, including SAHA, are 
currently at various stages of clinical development for solid malignancies, however, they showed 
only limited efficacy so far (302). The purpose of this study was to develop novel HDAC 
inhibitors with improved activity and reduced toxicity. Our data showed that the novel HDAC 
inhibitor St-1 exhibited anti-tumor activities that involve not only cell death, but also cancer stem 
cell inhibition.  
Like SAHA and MS-275, St-1induced cell death selectively in pancreatic cancer cells, but not in 
normal pancreatic ductal epithelial cells.  St-1 had lower IC-50 values compared to parent 
compounds  (210). St-1 induced caspase-3 cleavage more potently than SAHA and MS-275.  
The genomic land scape of PANC-1 and BXPC-3 cells is completely different (Table 1). Briefly 
speaking, BxPC-3 cells have wild type K-Ras and CDKN2A/p16, but express high level of pro 
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angiogenic cytokine cyclooxygenase 2 (COX2), whereas PANC-1 cells harbor mutations in K-
Ras, CDKN2A/p16 and p53, but have relatively low COX2 expression. The ability of St-1 to 
induce cell death in both pancreatic cancer cell lines that are different with respect to the  status 
of K-Ras, p53, CDKN2A/p16, and COX2 (7) suggested that St-1  can potentially  inhibit  
pancreatic tumors with heterogeneity.  
There are controversies regarding whether HDAC inhibitors could inhibit CSCs.  A number of 
small-molecule HDAC inhibitors have been reported to induce differentiation in several cancer 
cell lines (310). Contrary to these reports, Debeb et al. reported that SAHA and valproic acid 
promoted expansion of breast CSCs through dedifferentiation (311). Results from our studies 
showed that St-1 inhibited pancreatic CSCs with better potency than SAHA and MS-275. We did 
not observe an increase of sphere forming upon treatment with SAHA or MS-275.   It was also 
reported that HDAC inhibitors desensitize breast cancer cells to chemotherapeutic drug such as 
taxol. Our future studies will evaluate the effect of St-1 on inducing drug resistance.  
HDAC inhibition results in hyper acetylation of their target molecules such as histones. St-1 has 
broad specificity in HDAC inhibition and resulted in increased acetylation of all histones, just as 
SAHA and MS-275 (203, 312).  Different isoforms of HDACs have various locations, 
expression levels and functions. Nonspecific inhibition of HDACs resulted in toxic side effects 
(313).  Therefore, St-1 might have toxic side effects similar to its parent compounds.  Because 
St-1 is more potent, it is possible that St-1 might have a larger therapeutic index (Toxic dose 50 
(TD 50) ÷ Effective dose 50 (ED50)) when compared to its parent compounds.   Further studies 
evaluating the in vivo activity and toxicity of St-1 will serve as a guide for structure modification 
on St-1 or development of new St-1 derivatives aiming for better potency and less toxicity.  
Some HDAC inhibitors exert their anti-tumor actions by  interfering with additional targets other 
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than histones, such as p53 or α-tubulin (314). SAHA and St-1 induced α-tubulin acetylation, 
whereas MS-275 did not induce tubulin acetylation.  Because HDAC6 and Sirt-2 are the 
predominant enzymes that regulate α-tubulin acetylation, these data suggested that HDAC6 and 
Sirt-2 were also targets of St-1. 
Taken together, data here showed that St-1 is a novel HDAC inhibitor that showed better potency 
in vitro in inhibiting pancreatic cancer cells and CSCs, than the parent compounds SAHA and 
MS-275. More work is needed to assess its in vivo efficacy and toxicities.  
5.3. Part 2: St-3 as a novel HuR inhibitor 
5.3.1. Introduction 
One of our 28 tested HDAC derivatives, St-3, was more cyto-toxic and  more effective in 
inhibiting CSCs, cell migration and invasion compared to parent compounds, however, showed 
poor potency in HDAC inhibition. St-3 has a totally different mechanism of action. Using in 
vitro assays, we identified HuR as a target of St-3.  
HuR is a ubiquitously expressed RNA-binding protein that binds to the 5’-untranslated regions 
(UTR) or 3’ UTR of mRNA and regulates the transcript stability and translation (315). HuR 
recognizes and binds to adenine/uridine (AU) and U-rich elements (ARE) in the UTR of mRNA 
through RNA recognition motifs (RRMs). HuR contains three highly conserved RRMs and a 
variable basic hinge region between its RRM2 and RRM3. RRM1 and RRM2 mediate binding of 
HuR to ARE.  RRM3 and hinge region play a distinct role in formation of the cooperative HuR 
and ARE complex (316).  
HuR was initially discovered to be important for the normal development and maintenance of the 
nervous system in Drosophila melanogaster (317). HuR shares common structural similarities 
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with RNA binding proteins of the embryonic lethal abnormal vision (ELAV) protein family. 
HuR expressed in many cell types including adipose, intestine, spleen and testis. Other ELAV 
family members HuB, HuC and HuD are exclusively localized to terminally-differentiated 
neurons and therefore called the neuronal Hu proteins (318). 
HuR plays an important role in many pathologies, including chronic inflammation, cardio 
vascular diseases and cancer (319). HuR has been found to be abundant in pancreatic cancer as 
well as in many other types of cancers (320-323). HuR has been found to influence sensitivity of 
pancreatic cancer cells to gemcitabine by stabilizing the mRNA of gemcitabine metabolizing 
enzyme deoxycytidine kinase (324). HuR has also been found to enhance cancer cell invasion 
and metastasis by stabilizing mRNAs of MMPs, uPA, and Snail (325-328). HuR knockdown 
dramatically reduced cell growth in MCF7 breast cancer cells and invasive properties in MDA-
MB-231 breast cancer cells (329). As Snail is a critical repressor of E-cadherin, and E-cadherin 
repression is a hallmark of EMT, a potential link between HuR and EMT is indicated. Based on 
the above literature evidence, inhibition of HuR function is an attractive strategy to inhibit cancer 
development. In this study, we tested the activity of compound St-3 as a novel HuR inhibitor, 
and investigated the involvement of HuR in pancreatic cancer EMT. 
5.3.2. Results 
5.3.2.1. St-3 inhibited pancreatic cancer cell proliferation and invasion 
 As a structural analogue of SAHA and MS-275, St-3 affected the growth of pancreatic cancer 
cells in a more potent manner than the parent compounds (Fig. 5.5A, B). St-3 had IC50 values of 
21 µM for PANC-1 cells and 6.25 µM for BxPC-3 cells, while MS-275 had IC50 > 40 µM for 
both cell lines, and SAHA had IC50 of >40 µM for PANC-1 and 16 µM for BxPC-3 (Table 3).  
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Neither the parent compounds nor St-3 affected proliferation of hTERT-HPNE cells even at 40 
µM (Fig. 5.5C).  
To test the effect of St-3 on PANC-1 cell invasion and migration, we performed Boyden 
chamber invasion assay. PANC-1 cells seeded into the Boyden chambers that were precoated 
with matrigel were used to measure cell invasion.  Boyden chambers without matrigel coating 
were used to measure cell migration. At a sub-cytotoxic concentration of 2 µM, St-3 
significantly inhibited PANC-1 cells to migrate or to invade through Matrigel (Fig. 5.6). 
5.3.2.2. St-3 inhibited pancreatic CSCs. 
 Tumor spheroid formation assay was used to test the ability of St-3 in inhibiting CSCs. St-3 
inhibited the growth of the spheroids from BxPC3 cells at a concentration of 3 µM and 
completely eradicated the spheroid formation from PANC-1 cells at 10 µM (Fig. 5.7A, B). These 
concentrations were lower than IC50s to the bulk pancreatic cancer cell population. This data 
suggested that St-3 inhibited CSCs preferentially than the bulk population of cancer cells.  We 
further determined the expression of putative pancreatic CSC markers CD24, CD44 and 
EpCAM. Cells expressing all 3 markers are indicative for CSCs. Using immunofluorescence 
detection by flow cytometry, the percentage of CD24+CD44+EpCAM+ triple positive cells were 
detected. Significant reduction was found after only 24 hrs of treatment with 4 μM St-3 for 
BxPC3 cells and with 10 μM St-3 for PANC-1 cells (Fig. 5.7C). 
5.3.2.3. St-3 affected pancreatic cancer EMT markers. 
St-3 potently increased epithelial marker E-cadherin and decreased mesenchymal markers Snail 
and N-cadherin in PANC-1 cells. SAHA on the contrary enhanced Snail and N-cadherin, while 
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also slightly elevated E-cadherin level. This suggested that St-3 inhibits EMT by a mechanism 






















Figure 5.5- Cytotoxicity of SAHA, 
MS-275, St-3 on pancreatic cancer cell 
lines. Pancreatic cancer cell line PANC-
1 (A), BxPC-3 (B), and hTERT-HPNE 
cells (C) were treated with increasing 
concentrations of SAHA, MS-275, St-3. 
Cell viability was measured by MTT 
assay after 48hrs for PANC-1 and 
hTERT-HPNE cells, and after 24 hrs for 
BxPC-3. *, P<0.05 versus MS-275;  # 
P<0.05 versus SAHA, by T-test. 
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Figure -5.5C 
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Table 3- IC-50 vales of 






























ctrl St-3   2uM St-3  5uM 
ctrl St-3   2uM St-3  5uM 
Figure 5.6- St-3 inhibited pancreatic cancer cell invasion Matrigel 



















































Figure 5.7- St-3 inhibits pancreatic 
CSCs. A, B Cells were seeded at 4000 
cells/well in single-cell suspension into 
24-well ultra-low adherent tissue 
culture plates. PANC-1 was treated 
with 10 µM, and BxPC3 was treated 
with 3 µM of SAHA or St-3.  Spheroids 
were counted after 7 days. **, P<0.001 
by T-test. C.  The figures show 
CD44+EpCAM+ cells under the CD24+ 
gate. The CD24+CD44+EpCAM+ cells 
are putative pancreatic CSCs. St-3 
treatment at 4 µM (BxPC3), or 10 µM 
(PANC-1) for 24 hrs already repressed 








































































5.3.2.4. St-3 lost the ability to inhibit HDACs 
We then examined the activity of St-3 in inhibiting HDACs using SAHA and MS-275 as positive 
controls. As expected, SAHA and MS-275 increased the acetylation of all 4 histones (H2A, H2B, 
H3, and H4). However, St-3 showed much weaker potency in HDAC inhibition than SAHA and 
MS-275.  St-3 did not enhance α-tubulin acetylation (Fig. 5.9). These results suggest that St-3 
Figure -5.8A 
Figure 5.8- St-3 affects EMT marker 
proteins. PANC-1(A) and BxPC-3 (B) 
cells were exposed to SAHA, MS-275, 
St-3 or vehicle control for 24 hrs and 
then E-cadherin expression was 
detected by western blot. C. PANC-1 
cells were treated with 10 µM of 
SAHA and St-3. The pattern showing 
E-cadherin up and Snail and N-







did not exert its anti-pancreatic cancer activity through HDAC inhibition but rather through a 





Figure 5.9- St-3 loses activity to inhibit HDAC. PANC-1(A) and BxPC-3 (B) cells 
were exposed to SAHA, MS-275, St-3 or vehicle control for 24 hrs and acetylation of 
histones and α-tubulin was detected by western blot. Actin was a loading control. 
 







Figure 5.10- St-3 inhibits HuR binding to 
mRNA. A. Fluorescence polarization assay. 
Twenty five nM full-length human HuR and 2 
nM FITC-labeled 16-nt Msi1 RNA sequence 
was used. B. Alpha assay. 100 nM His-tagged 
HuR RRM1/2 fragment and 25 nM biotinylated 
16-nt Msi1 RNA sequence were used. Labeled 
scramble 16-nt RNA was used as control. Ki 
values were calculated based on the Kd and the 
dose-response curves. C-D. SPR analyses of 
St-3 binding to immobilized full length HuR, 
RRM1 and RRM1-2. Increase in refractive 




5.3.2.5. St-3 inhibited HuR binding with target mRNA 
Instead of HDAC inhibition, St-3 potently inhibited binding of HuR to its target mRNAs. In a 
fluorescence polarization assay, St-3 inhibited binding of HuR protein to its known target Msi1 
mRNA with IC50 and Ki of 6.9 µM and 0.8 µM respectively (Fig. 5.10A). The Alpha assay, 
another bead-based technology widely used to analyze protein-protein interactions, and their 
inhibitors, was employed to monitor the interactions between RRM1/2 of HuR and its target 
RNA MSi1 in presence of St-3 (Fig. 5.10B). St-3 inhibited binding, with IC50 and Ki of 2.2 µM 
and 0.7 µM respectively (Fig. 5.10A, B). In contrast, SAHA did not show any inhibitory effect 
on HuR/Msi1 mRNA binding in both the assay. Data from fluorescence polarization assay or 
Alpha assay do not indicate whether St-3 is binding to HuR or RNA. Therefore, SPR analysis 
was performed to detect the direct interaction between HuR and St-3. SPR results suggested that 
St-3 bound to either full-length HuR or the RNA Recognition Motifs of HuR (RRM1/2) (Fig. 
5.10C, D) as shown by increase in resonance (RU).   
5.3.2.6. St-3 blocked HuR function 
HuR binds to the 3’-UTR of target mRNAs, stabilizing the mRNAs and promoting translation. In 
order to determine the functional consequence of St-3 on downstream targets of HuR, real time 
PCR assay was performed on gene transcripts of putative HuR targets. HuR has a broad range of 
target mRNAs that involve in cell survival, proliferation, angiogenesis, anti-apoptosis, and 
reduced immune recognition (1). Here, we focused on a sub-set of genes related to EMT, CSC 
and metastasis (Table 4). St-3 treatment at 5 and 10 µM, which were below IC-50, reduced β-
catenin, Msi1, urokinase plasminogen activator surface receptor (UPAR), and low density 
lipoprotein receptor-related protein 6 (LRP 6) to different extents (Fig. 5.11A). As these gene 
products are important in pathways regulating EMT, CSC and metastasis, the data is consistent 
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with inhibitions induced by St-3 in pancreatic cancer cell EMT, CSC and metastasis. Especially, 

















Table 4- Putative HuR target mRNAs that play an important role in cancer cell 

















Snail mRNA was reported as a direct target of HuR (328). To further confirm that St-3 disrupted 
HuR function on stabilizing target mRNAs, the stability of Snail mRNA was examined in 




































Figure 5.11- St-3 blocks HuR 
function and reduced HuR target 
mRNA stability. (A)  Real time PCR 
determining the effect of St-3 on 
HuR target expression. (B) Stability 
of Snail mRNA after St-3 treatment, 
HuR knockdown (Si-HuR), HuR 
over expression (tran-HuR), studied 




and RT-PCR was done at indicated time points to detect Snail mRNA.  As comparisons to St-3 
treatment, HuR was either knocked down using SiRNA in PNAC-1 cells or was transfected and 
overexpressed. The results showed that over expression of HuR stabilized Snail mRNA, while 
knockdown of HuR enhanced Snil mRNA degradation (Fig. 5.11B). St-3 treatment mimicked 
HuR knockdown in enhancing Snail mRNA degradation (Fig. 5.11B). 
5.3.3. Discussion 
In this current study, we serendipitously developed St-3 as a novel HuR inhibitor. St-3 was 
synthesized as a derivative of SAHA and MS-572. However, it exhibited totally a different 
mechanism of action. St-3 was more potent than the parent compounds in inhibiting pancreatic 
cancer cell proliferation, invasion, migration, as well as EMT and CSCs.  Our in vitro data 
suggested that St-3 executed its function by inhibiting HuR binding to its target mRNAs.  
A mounting body of literature suggests that HuR has a central role in cancer. The HuR target 
mRNAs encode a variety of factors required for cancer cell proliferation, survival, angiogenesis, 
invasion and metastasis. Both HuR expression and subcellular localization is aberrant in human 
tumor tissues. In response to various stimuli, HuR moves from nucleus to cytoplasm to stabilize 
target mRNA to promote cancer progression (323). Inhibition of HuR function by St-3 could be 
expanded into other cellular pathways and outcomes related to tumor progress. 
Inhibitors that block the HuR and ARE interactions could be ideal tools for cancer therapy. 
However, due to lack of a well-defined binding pocket, limited success has been made in 
identifying small-molecule inhibitors that directly block the HuR and ARE interactions. Using 
RNA electrophoretic mobility shift assay Chae et al., identified that quercetin, b-40, b-41 
strongly inhibited binding of HuR to its well-known target TNF- mRNA in vitro (330). Meisner 
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and coworkers have shown that dehydromutactin, MS-444 and okicenone interfered with HuR 
function by inhibiting its homodimerization (331). More studies are needed to investigate these 
compounds for their anti-tumor activities. The chemical structure of St-3 has low similarity to 
those of quercetin, b-40, b-41, dehydromutactin, MS-444 and okicenone, suggesting that St-3 
might have different binding sites on HuR or might execute a different mechanism of HuR 
inhibition. The previously reported compounds are all structurally independent; therefore, they 
cannot provide information for structure activity relationship (SAR) studies to define a binding 
pocket, or for rational design of potent and specific HuR inhibitors. St-3 and its structural 
analogues could potentially be used as a tool in the study of binding pocket of HuR. 
The role of HuR in EMT is not well understood. Only one published study proposed Snail as a 
target of HuR in MCF-7 breast cancer cells (328). Our data here showed that in pancreatic cancer 
cells, overexpression of HuR stabilized Snail mRNA, whereas knockdown of HuR enhanced 
Snail mRNA degradation. As a HuR inhibitor, St-3 also reduced Snail mRNA. This provided 
additional evidence for Snail as a target for HuR. Also, it provided evidence supporting a role of 
HuR in EMT regulation.  
By reducing Snail expression, St-3 enhanced E-cadherin expression, and decreased expression of 
the mesenchymal marker N-cadherin. These changes represented reversal of EMT. In contrast, 
SAHA enhanced both E-cadherin and N-cadherin expression in PANC-1 cells. Several studies 
have demonstrated that overexpression of N-cadherin promotes motility, invasion and metastasis 
even in the presence of E-cadherin (332, 333). This could potentially be one of the reasons for 
the lack of therapeutic benefit when SAHA was used to treat solid tumors.  
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 Inhibition of HuR provides disruption in oncogenic pathways that are preferentially active in 
pancreatic cancer cells relative to normal cells. Therefore, St-3 showed more potent cyto-toxicity 
against PANC-1 and BxPC-3 cells compared to HDACs but was not toxic to hTERT-HPNE 
cells. However, St-3 might possess some in vivo toxicity. Some predictions can be made from 
recent studies showing that HuR depletion resulted in apoptosis of progenitor cells in the bone 
marrow, thymus and intestine. This is because HuR may directly regulate the expression of 
Mdm-2 at the post transcriptional level (334) and therefore depletion of HuR resulted in 
decreased Mdm2 and increased p53 and its downstream effectors critical for cell death. More 
research is needed to explore the mechanism of cell death caused by St-3. 
 Beta catenin was depleted with St-3 treatment, which plays an important role in stem cell self-
renewal. Data here suggested that St-3 might block HuR interaction with β-catenin mRNA and 
thereby promoted β-catenin mRNA degradation.  A recent study by D’Uva and colleagues 
showed that β-catenin stabilizes SNAI2 and carbonic anhydrase 9 mRNA in cooperation with 
HuR under hypoxic condition in breast cancer cell lines to induce stem cell features (335).  It is 
possible that a similar mechanism exists in pancreatic tumor tissues under hypoxic condition. 
Inhibition of β-catenin mRNA and HuR interaction by St-3 warrants further investigation.  
In conclusion, we investigated the link between HuR and EMT related genes, and developed a 
novel HuR inhibitor St-3 which exhibited inhibitory activities to pancreatic cancer cell growth, 
metastasis, EMT and CSCs. The novel compound St-3 could serve as a tool for study of the 
HuR-RNA interaction. Moreover, data in this chapter provided a basis and mechanistic evidence 























Drug screening assays based on cytotoxicity usually do not identify compounds that specifically 
target CSCs, because CSCs comprise only a small portion of the cancer cell population, and it is 
difficult to propagate stable CSC populations in vitro for HTS assays. To establish an efficient 
way for discovery of drugs that preferentially inhibit CSCs, we developed an immunofluorescent 
assay for HTS to identify inhibitiors of cancer cell EMT, which is highly associated with cancer 
cell metastasis and “stemness”. Using this assay, 4 chemical libraries containing a total of 41,472 
compounds were screened for their ability to induce E-cadherin expression in PANC-1 
pancreatic cancer cell line. HTS identified 1,584 hits with the initial screening, using automated 
microscopy for a cell-by-cell fluorescence intensity analysis. A secondary screening among the 
initial hits refined the number of positive hits to 73. Each of these 73 compounds was tested at 8 
concentrations ranging from 0.15 to 30 µM. Among them, 17 exhibited concentration-dependent 
induction of E-cadherin expression. Based on chemical structure and availability, we selected 6 
compounds which belonged to 2 different chemical structural clusters for evaluation of EMT and 
CSC inhibition. A novel compound 1-(benzylsulfonyl) indoline (BSI, Compound #38), 
significantly inhibited pancreatic cancer cell migration and invasion. BSI induced Histone 3/4 
acetylation resulted in E-cadherin up-regulation. Moreover, BSI effectively inhibited tumor 
spheroid formation, which is an indicator of CSC inhibition. Six analogues of BSI were tested 
but did not show superior anti-migration or anti-CSC activities compare to BSI. This study 
demonstrated a new and feasible approach for discovery of agents targeting EMT and CSCs 
using HTS, and identified a class of novel chemicals that could be developed as anti-EMT and 





Few approaches have been described to directly screen for agents that are specifically cytotoxic 
to CSCs. One reported HTS approach involves utilizing a genetically modified breast cancer cell 
line that has low expression of a cell adherent protein E-cadherin and is therefore forced into a 
mesenchymal status (336). Other approaches use suspension cultures of tumor spheroids as an 
indication of CSCs (337). The challenge is likely due to two reasons: first, although CSCs can be 
identified and isolated by cell surface marker profiles, and tumor spheroids are cultured in vitro, 
it remains difficult to propagate a stable, undifferentiated CSC population in cell culture suitable 
for HTS for many solid tumors. Moreover, because CSCs comprise only a small portion of 
cancer cell populations, standard high-throughput cytotoxic assays applied to bulk populations of 
cancer cells do not identify agents with CSC-specific toxicity.  
Among the biological properties of CSCs, one that is highly associated with the phenotypic 
characteristics identified in the induction of cancer cells is EMT. EMT is an important initial step 
during the complicated process of cancer cell dissemination and metastasis, characterized by 
progressive loss of epithelial markers, such as E-cadherin (95, 122, 338-343). Loss of cell 
surface E-cadherin is a classical hallmark of EMT (344). Studies have shown that loss of E-
cadherin was the rate limiting step in the progression from adenoma to carcinoma and the 
subsequent formation of metastasis (345, 346). In this study, we aimed to establish a HTS assay 
to simply identify compounds that can restore E-cadherin, in the hope of discovering inhibitors 





6.3.1. Development of HTS assay based on immunofluorescence detection of E-cadherin 
expression  
To establish the HTS assay, we selected a pancreatic cancer cell line that possesses an “EMTed” 
profile and has inducible E-cadherin. Three pancreatic cancer cell lines were examined for their 
basal expression of epithelial (E-cadherin, ZO-1) and mesenchymal markers (N-cadherin, 
Vimentin), as well as transcriptional repressors of E-cadherin (Snail-1 and Zeb-1) (Fig.6.1 A-E). 
MIA PaCa-2 was highly mesenchymal in nature with undetectable levels of E-cadherin, whereas 
HPAF-2 is highly epithelial in nature with a high level of E-cadherin expression. PANC-1 cells 
were mesenchymal in nature, as shown by low levels of epithelial markers (E-cadherin and ZO-
1) and relatively high levels of EMT transcription factors (Snail and Zeb), making it potentially 
suitable for development of the HTS assay. We then examined whether E-cadherin expression 
could be induced in PANC-1 cells. Indeed, 1-4 mM of sodium butyrate, a histone deacetylase 
inhibitor (347), induced E-cadherin in PANC-1 cells concentration dependently (Fig.6.2). CSC 
populations at baseline were detected in PANC-1 cells using multi-fluorescence labeled flow 
cytometry to identify CD24+CD44+ EpCAM + cells (150). The triple positive cells comprise 
~1.3% of the PANC-1 bulk population (Fig.6.3A). Moreover, PANC-1 cells were resistant to 
gemcitabine treatment, with 100 µM gemcitabine only achieving 60% inhibition (Fig.6.3B). 
Therefore, PANC-1 was selected to be used in HTS for detection of E-cadherin induction. 
Immunofluorescent assay for detection of E-cadherin was established in a 96-well plate and 
transformed into a 384-well plate and optimized for automation with HTS, using a primary 
antibody for E-cadherin recognition, and a secondary antibody conjugated to a red fluorophore, 































Figure -6.1D Figure -6.1E 
Figure 6.1- Baseline features of PANC-1, MIA PaCa2, and HPAF-2 pancreatic cancer 
cells in EMT related gene expression. A. Western blot for E-cadherin, Claudine, vimentin, 
Snail expression in all 3 pancreatic cancer cell lines.  B-E. mRNA levels of E-cadherin (E-
Cad), Zo-1, Zeb-1 and Snail-1. RT-PCR data was normalized to 18s rRNA and represented as 



























Figure 6.2- Sodium butyrate induced E-
cadherin expression in PANC-1 cells. 
Western blot for E-cadherin expression in 
PANC-1 cells treated with sodium butyrate. 
 
Figure -6.2 
Figure 6.3- PANC-1 cells are enriched with 
CSC population and are resistant to 
gemcitabine A. Flow cytometry identification 
of CSCs in PANC-1 cells. CD24+CD44+ 
EpCAM + subpopulation were detected as 
pancreatic cancer CSCs. PANC-1 cells were 
triple stained with PE-conjugated anti-CD24, 
PE-Cy7-conjugated anti-CD44 and APC-
conjugated anti-EpCAM. DAPI staining was 
used for identification of living cells. Cells were 
analyzed with multi-label flow cytometry. The 
upper panel represents CD24+ gated population 
(25.8%), and the lower panel represents CD444+ 
EpCAM + cells within the CD24+ population. 
CSCs comprises about 1.29% of the bulk 
PANC-1 cells (25.8% × 5%). B. Resistance of 
PANC-1 cells to gemcitabine treatment. PANC-
1 cells were treated with gemcitabine and 
viability was determined at 72 hrs of incubation 
by MTT assays. Data represent Mean ± SD of 
triplicate measurements of 4 individual 
experiments. Gemcitabine concentrations up to 




















To avoid a possible high rate of false positives with the whole plate fluorescence intensity 
detection, we used the BD Pathway automated microscopy to carry out High Content Screening 
(HCS), which takes into account not only fluorescence intensity, but also nuclei size and shape, 
to ensure fluorescence comes from living cells. The assay was able to reproducibly detect 
increases in E-cadherin in PANC-1 cells in response to 3.5 mM sodium butyrate (Fig. 6.4A, B). 
Using this instrument, a validation screening was carried out on 3,168 compounds at the 
concentration of 10 µM from Microsource and Prestwick compound libraries. Compounds in 
these libraries have known functions and diverse applications. The screening detected 84 
compounds with low cytotoxicity (<25% cell loss) and increased fluorescence by 3 standard 
deviations above average, which represented a 2.65% positive rate (Fig. 6.4C).  
6.3.2. Identification of compounds that induces E-cadherin expression by HTS 
A larger compound library, Chembridge library containing 41,472 compounds with structural 
diversity and drug like properties, was screened using the HTS assay. HTS resulted in 1,500 
positive hits at the concentration of 10 µM. To rule out auto-fluorescent compounds that have an 
emission overlapping with Alexa Fluor 594, we performed a secondary screening using an 
antibody conjugated to a green fluorophore, Alexa Fluor 488. The secondary screening was 
carried out over the 1,500 initial hits from Chembridge library and the previous 84 hits in the 
assay validation screening. The secondary screening identified 73 compounds that had 































Figure 6.4- Validation of the 
immunofluorescent HTS assay. A. 
Average signal and standard deviation of 
the positive and negative controls, 
compared to the average of all screened 
compounds. A total of 3,168 compounds 
were from Microsource (2,320 
compounds) and Prestwick (848 
compounds) compound libraries. Every 
plate included 16 wells of vehicle (0.35% 
DMSO) treated cells, and 16 wells of 
cells treated with 3.5 mM sodium 
butyrate (SB).  Avg +1, +2 and +3 
represent signals 1, 2 or 3 standard 
deviations above average.  B. 
Representative images of E-cadherin 
immunofluorescence of PANC-1 cells 
treated by 0.35% DMSO, or 3.5 mM 
sodium butyrate (SB). E-cadherin was 
detected by anti-E-cad primary antibody 
(1:250 dilution) followed by Alexa594 
conjugated secondary antibody (1:500 
dilution). C. The relative fluorescence 
(ratio of Alexa Fluor to Hoechst, fold 
over DMSO vehicle) was plotted against 
individual wells to visualize the data 
spread. The median for control wells 
(DMSO vehicle) was 1-fold, with a 0.1-
fold standard deviation. The HCS assay 
cutoff was 3 standard deviations above 
the median (1.437-fold), marked by the 
red line. Eighty four compounds had 








These compounds were then retested at 8 concentrations in a dose response ranging from 0.15 to 
30 µM. Of the 73 compounds, 17 showed dose responsive increases in both Alex594 and 
Alex488 fluorescence in PANC-1 cells (Fig. 6.6).     
6.3.3. Validation of active compounds for E-cadherin restoration  
Based on availability and structures, we selected 6 novel compounds for further testing, which 
belong to 2 different structural clusters. Compounds 150, 717, 743 are vinyl quinolone 
compounds (Cluster#1) and compounds 38, 353 681 are sulfonyl indoline compounds 
(Cluster#2) (Fig. 6.7). Compounds in both clusters showed low cytotoxicity (IC50 > 50 M) 
towards PANC-1 cells except for compound 150 (IC50 = 2 M, in Cluster#1) and compound 353 
(IC50 = 22 M, in Cluster#2). Overall, compounds in cluster#1 were more cytotoxic compared 
with compounds in Cluster#2. Cytotoxicity of the compounds in both clusters was also tested on 
BxPC-3 and L3.6pl pancreatic cancer cells and similar results were obtained (Fig. 6.7).  
Western blotting in total cell lysate showed that at 5 and 10 µM, BSI in cluster#2, marginally 
increased E-cadherin expression in PANC-1 cells and showed a concentration dependence. 
Compound 150 in cluster#1 decreased E-cadherin protein level at 0.5 and 1 µM, probably 
because of cytotoxicity and other compounds did not show effects (Fig. 6.8A). Increased 
concentrations in cluster#2 compounds confirmed that BSI induced E-cadherin expression in 

































Figure 6.5- A. Scheme of the HTS. B. The percent of red fluorescence, 
relative to DMSO vehicle, was plotted against individual wells to 
visualize the data spread. The red line represents 3 standard deviations 









































Figure 6.7- Six selected compounds structure, cytotoxicity and validation for E-
cadherin induction Sensitivity of PANC-1 cells to 6 selected compounds. Cells were 
exposed to different concentrations of selected compounds for 48hrs. Cell viability 
detected at 48hrs post treatment by MTT assay. E-cadherin immunofluorescence of 
PANC-1 cells treated by 6 selected compounds. E-cadherin was detected by anti-E-cad 
primary antibody (1:250 dilution) followed by Alexa 488 conjugated secondary antibody 





















6.3.4. BSI increased E-cadherin expression by inhibition of Snail and HDACs 
While E-cadherin was increased, decrease in the expression of Snail was detected in PANC-1 
cells treated with BSI (Fig. 6.9). Snail is one of the major E-cadherin transcriptional repressors in 
pancreatic cancer cells. Snail recruits HDACs to induce epigenetic changes, resulting in a closed-
chromatin configuration of DNA, and thus inhibits E-cadherin expression (200, 348). We 
investigated the HDAC activities by detecting acetylation of histones in PANC-1 cells. At 24 hrs 
of BSI treatment, there was a robust increase in H3 lysine 9 (H3-K9) acetylation and H4 (H4-
K8) acetylation compared to control cells (Fig. 6.9). H2A acetylation increased also (Fig. 6.9), 
Figure -6.8A 
Figure -6.8B 
Figure 6.8- BSI increased E-cadherin expression in PANC-1 cells. A. Western blot 
analysis of E-cadherin in PANC-1 cell that were exposed to two different concentrations of 
cluster#1 and cluster#2 compounds. B. Western blot analysis of E-cadherin in PANC-1 cells 





indicating inhibition of HDACs. This mechanism is consistent with published data showing that 
H3/H4 deacetylation silenced E-cadherin (348, 349). Taken together, BSI (compound 38) was 













6.3.5. BSI inhibited pancreatic cancer cell invasion and migration 
Boyden chambers covered with Matrigel were used to examine the ability of BSI to inhibit 
PANC-1 cell invasion, while chambers without Matrigel coverage were used to examine cell 
migrating ability.  Data showed that BSI significantly decreased both invasion and migration of 
PANC-1 cells at 24 hrs treatment at a sub-cytotoxic concentration of 25 µM (Fig. 6.10A).  
Scratch assay was used to confirm these inhibitory effects of BSI. BSI at 25 µM significantly 




Figure 6.9- BSI increased E-cadherin expression by inhibition of Snail and 
HDACs.  Western blot analysis of E-cadherin, Snail, H2A-Lys5, H3-Lys9, H4-Lys8 
























Figure 6.10- BSI inhibited cell invasion and migration of pancreatic cancer cells A. 
Matrigel invasion assays for pancreatic cancer cell migration and invasion. PANC-1 cells 
were exposed to 25 µM BSI. Cell migration (without Matrigel) and invasion (with 
Matrigel) were detected at 24hrs. Bar graph shows the average number of 
migrated/invaded cells per field. B. Scratch assay for pancreatic cancer cell migration. 
Scratch was made on confluent monolayer of BxPC-3 cells and then exposed to 25 µM 
BSI. Cell migration was measured at 24 and 30 hrs of post-BSI treatment. Bar graph shows 





























































6.3.6. BSI inhibited pancreatic tumor spheroids formation 
The self-renewal capacity is one of the major characteristics of CSCs. Tumor spheroid formation 
ability in suspension culture is indicative for this feature (121). Primary and secondary tumor 
spheroid formation was examined in BxPC-3 cells treated with BSI. BSI significantly reduced 
the number and size of the primary and secondary spheroids in pancreatic cancer cell lines (Fig. 
6.11A-C).  
6.3.7. Analogues of BSI inhibited pancreatic cancer cell migration, invasion, and tumor 
spheroids formation 
Six more analogues of BSI were purchased from Chem Bridge Chemical Store (Fig. 6.12) and 
tested for their effects on pancreatic cancer cell migration, invasion and tumor spheroid 
formation. All of these compounds possessed low cytotoxicity towards PANC-1 and BxPC-3 
cells (Fig. 6.12). Compounds 16, 288, 480, 704 and 935 have comparable activities in inhibiting 
cell migration, as evaluated by wound healing scratching assay (Fig. 6.13).  These compounds 
also inhibited spheroid formation of PANC-1 and BxPC-3 cells, with reduction in both numbers 
and sizes of spheroids (Fig. 6.14, 6.15). However, these analogues did not show superior effects 



























Fig. 6.11 BSI reduced the pancreato sphere 
formation BxPC-3 cells in ultra-low attachment 
plates exposed to 25 µM of BSI.  A. Primary 
Spheroids were imaged and counted 14 days post 
treatment. Primary spheroids were dissociated into 
individual cells using trypsin and then reseeded 
into ultra-low attachment plates for secondary 
spheroids. Again cells exposed to 25 µM of BSI. 
Secondary Spheroids were imaged and counted 14 
days post treatment. Scale bar 500 µm. 
Magnification of the images 100X.  B. Bar graph 
representing the average number of spheroids. C. 
ferret diameter of spheroids ± SEM. *, P<0.05 by 
T-test 




























Figure 6.12- Structure and cytotoxicity of BSI analogues Sensitivity of pancreatic cancer 
cells (PANC-1 and BxPC-3) cells to BSI analogues (16, 288, 480, 484, 704, and 935). Cells 
were exposed to different concentrations of BSI analogues for 48hrs. Cell viability detected at 





























Figure 6.13- BSI analogues inhibited cell migration Scratch assay for cell 
migration. Scratch was made on confluent monolayer of BxPC-3 cells using 1.25 
ml sterile pipette tip.  After washing with media, cells were exposed to 25 µM BSI 
analogues (16, 288, 480, 704, and 935). Scratch was photographed at 0, 24 hrs post 




















































































Fig. 6.14 -6.15 -  BSI analogues are not as efficient as BSI in inhibiting  pancreato sphere 
formation   BxPC-3 and PANC-1 cells were seeded in ultra-low attachment plates and then 
cells were exposed to 25 µM of  BSI  analogues (16, 288, 480, 704, and 935).  BxPC-3 (Fig. 
6.14A) and PANC-1 (Fig. 6.15A) primary spheroids were imaged and counted 14 days post 
treatment. Bar graph representing the average number of primary spheroids (Fig.6.14B, 6.15B), 
feret diameter of the spheroids (Fig. 6.14C, 6.15C)± SEM. Primary spheroids were dissociated 
into individual cells using trypsin and then reseeded into ultra-low attachment plates for 
secondary spheroids. Again cells exposed to 25 µM of BSI analogues. BxPC-3 (Fig. 6.14D) and 
PANC-1 (Fig. 6.15D) Secondary Spheroids were imaged and counted 14 days post treatment. 
Bar graphs representing the average number of secondary spheroids (Fig. 6.14E, 6.15E), feret 
diameter of the spheroids (Fig. 6.14D, 6.15D) ± SEM. Scale bar 500 µm. Magnification of the 













The challenges in investigating CSC inhibitors are reflected in the challenges faced in the 
development of treatment strategies for pancreatic cancer. CSCs are proposed to be the driving 
force of the tumor’s high metastasis rate and recurrence rate which directly result in extremely 
poor prognosis and treatment outcomes for patients (137, 150, 350). As direct screening is 
difficult for CSC-toxic compounds, our study provided an alternative screening for EMT 
inhibitors as an initial step for development of CSC inhibitors. The rationale has its roots in the 
close association between EMT and CSCs, as studies showed many genes, transcriptional factors 
and signaling pathways that induce EMT are also important in CSC transformation and 
maintenance (58, 59) . Therefore, looking for EMT inhibitors holds the hope of also discovering 
CSC inhibitors. Furthermore, because loss of E-cadherin expression is associated with metastasis 
in many neoplasms (351-354), EMT inhibitors can be extremely useful by themselves for anti-
metastasis, even if they do not inhibit CSCs. As a proof of this concept, our screening for E-
cadherin inducers resulted in identification of the novel compound BSI as a potent EMT 
inhibitor. BSI inhibited pancreatic cancer cell migration/invasion and also strongly inhibited 
CSCs. 
Loss of E-cadherin, a classic hallmark of EMT, can occur by either genetic or epigenetic 
alterations (303, 355). Recent reports suggested that histone acetylation regulated E-cadherin 
expression. Transcriptional repressors of E-cadherin, i.e. Snail1/2 and Zeb1/2, recruit HDACs to 
conduct an epigenetic alternation that inhibits E-cadherin gene transcription (79, 80).  Our hit 
compound BSI substantially increased H3 and H4 acetylation, indicating HDAC inhibition as its 
mechanism of action. Other mechanisms are not excluded for BSI’s activity in inhibiting CSC.  
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Further in-depth mechanistic studies are worth carrying out, given the anti-CSC potential of this 
cluster of compounds.  
Hydroxamic acid or benzamide groups are the functional groups in (previously) known HDAC 
inhibitors are either (356). BSI and its analogues studied here do not contain these structural 
groups but are instead, benzyl sulfonyl indoles. These data have therefore revealed a new class of 
potent HDAC inhibitors that possesses in vitro anti-EMT and anti-CSC activities, with low 
cytotoxicity. Additional novel drugs and drug leads can presumably be developed based on 
further studies using the SAR. Because these compounds were not generally cytotoxic, safety 
and low toxicity can probably be expected in future in vivo studies.   
In conclusion, we have shown the development and application of novel HTS for compounds 
that induces E-cadherin induction in pancreatic cancer cell lines, as an approach for CSC 
inhibitor identification. Furthermore, our novel BSI compound inhibited pancreatic cancer EMT 


































Pancreatic cancer continues to be one of the most lethal human malignancies. By 2030, 
pancreatic cancer is expected to become the second-leading cause of cancer-related deaths in the 
United States (357). Though the oncology community has made significant progress in 
understanding pancreatic cancer biology, there are no effective therapies available to date, 
because of its multifactorial nature. At the cellular level, neoplastic cells harbor activating K-Ras 
mutations at high frequencies in pancreatic cancer patients.  Pharmacological agents targeting K-
Ras for pancreatic cancer are currently an active area of research (358). However, it is possible 
that blocking K-Ras function may not be sufficient to treat pancreatic cancer, because these 
cancer cells may adapt to K-Ras inhibition either by overexpressing or mutating genes in 
downstream pathways of K-Ras.  Several other growth factor signaling pathways also impact 
disease progression and pathogenesis, which might drive growth and cell survival in the absence 
of K-Ras signaling (359). Layered on top of oncogenic mutations are a host of tumor suppressor 
gene inactivations (360). Developing effective anticancer regimens against changes of tumor 
suppressor pathways has emerged to be a promising area of research (52). Novel approaches 
need to be investigated with an open mind, as new knowledge and concepts in pancreatic cancer 
biology develop.  
CSCs are a relatively new concept in cancer biology. A growing body of literature suggests that 
pancreatic tumors are enriched with CSCs (361).  CSCs are frequently associated with metastatic 
foci and chemoresistance and are increasingly linked to an EMT phenotype (121, 362). The 
resistance to chemotherapy of this subpopulation is responsible for tumor recurrence. EMT in 
cancer cells is triggered by several different signaling pathways, which then activate a set of 
transcription factors to induce EMT (79, 86). Therefore, inhibitors of EMT signaling pathways or 
the transcription factors hold the promise to inhibit pancreatic cancer metastasis and CSCs. Due 
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to lack of therapeutic benefit with the currently available EMT inhibitors, this dissertation took 
several novel approaches to target pancreatic cancer cell EMT. The key findings can be 
summarized as follows. 
Chapter 4 demonstrated that ascorbate at pharmacological doses was a potent inhibitor of 
pancreatic cancer cell EMT, cell invasion and migration. Ascorbate treatment resulted in 
decreased expression of several mesenchymal markers and enhanced expression of epithelial 
markers. Ascorbate treatment inhibited pancreatic cancer cells spheroid formation, suggesting 
CSC inhibition. In addition, ascorbate enhanced α-tubulin acetylation and stabilized microtubule 
polymers to inhibit cancer cell metastasis and mitosis, by regulating expression and activity of 
HDAC6 and Sirt-2. Tumor microenvironment and desmoplasia were influenced resulting in 
inhibited cancer cell metastasis. These data provide a basis to direct clinical research focusing on 
tests of efficacy of IVC in pancreatic cancer patients.  
Several phase 1 and 2a studies have been carried out using high dose intravenous ascorbate in 
cancer treatment. These studies confirmed its safety and implied its benefit especially in 
combination with current chemotherapies (266, 276, 277). However, no definitive phase 2 study 
has been done. Given the very limited treatment options for pancreatic cancer patients, the 
compelling preclinical data showing effectiveness and potential benefits of high dose intravenous 
ascorbate, demonstrate a need for designing and conducting clinical trials to definitively test the 
efficacy of ascorbate.  
Mechanistically, one of the most interesting findings from data presented here is that ascorbate 
treatment resulted in enhancement of the collagen content in tumor stroma. Tumor stroma plays 
an important role in tumor growth and progression. Recent studies showed that desmoplasia in 
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pancreatic tumor stroma restrain the tumor growth rather than supporting it (226, 280). 
Therefore, it is worthwhile to test how high-dose ascorbate effects the tumor growth and 
metastasis at different stages of the disease pathogenesis using a transgenic mouse model system 
such as PKCY.  
 The mechanism of CSC inhibition by ascorbate needs to be further studied.  One possible 
approach is to evaluate the influence of ascorbate on Wnt/β-catenin, Notch, and SHH pathways. 
Understanding such basic mechanisms will provide clues for novel combination treatment 
approaches. Ascorbate holds the advantage of low toxicity.  Assessment of such combination 
treatments in preclinical models will provide valuable tools for testing them in clinical settings 
for pancreatic cancer patients. Our in vitro studies showed that ascorbate worked synergistically 
with HDAC inhibitors.  In vivo evaluation of this finding is another important avenue that should 
be studied in the future.  
Another interesting finding is that ascorbate mediated regulation of HDAC6. Though HDAC6 is 
primarily localized to cytoplasm, recent studies have shown that HDAC6 can be localized to the 
nucleus to regulate histone acetylation and gene transcription (363). Future studies can be 
undertaken to study the effect of ascorbate on HDAC6 nuclear localization and its influence on 
histone acetylation. Mechanisms of HDAC6 expression regulation by ascorbate need to be 
characterized in detail. Saji and colleagues showed that HDAC6 expression is regulated by 
estrogen signaling in estrogen receptor (ER) α positive breast cancer cells (364). However, the 
role of ER in pancreatic cancer neoplasms remains unknown (365). Our future studies will 
evaluate if ascorbate regulates HDAC6 expression through estrogen signaling. In addition to α-
tubulin, HDAC6 has several additional substrates such as heat shock protein 90 (Hsp90) (366), 
heat shock cognate protein 70, myosin heavy chain 9 (MHC9), and dnaJ homology subfamily A 
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member 1 (367). HSP90 chaperon activity is regulated by reversible acetylation and controlled 
by HDAC6. Inhibition of HDAC6 leads to hyper acetylation of HSP90 and a loss of chaperon 
activity (366). Future studies need to be conducted to explore HSP90 acetylation status and its 
chaperon function after ascorbate treatment in pancreatic cancer cells. It would also be worth 
testing the anti-cancer effects of ascorbate and HSP90 inhibitor combination in both in vitro and 
in vivo. 
Data here also demonstrated that ascorbate treatment depletes NAD+ levels in pancreatic cancer 
cell lines. The mechanism of NAD+ depletion as a result of ascorbate treatment needs to be 
investigated in detail. We have recently showed that ascorbate caused DNA damage and PARP 
activation (266). PARP activation might result in NAD+ depletion. It is also possible that 
ascorbate might alter NAD+ biosynthesis (de novo and salvage) pathways. Real-time PCR or 
western blotting can be performed to test the effect of ascorbate on the expression of key 
enzymes that mediate NAD+ biosynthesis through de novo pathway (indoleamine 2,3-
dioxygenase, quinolinate phosphoribosyl transferase, nicotinamide (NAM) mononucleotide 
adenylyl transferase (NMNAT),  NAD+ synthase ) and salvage pathway (NAM phosphoribosyl 
transferase, NMNAT, nicotinamide  riboside kinase, nicotinic acid phosphoribosyl transferase) 
(368). Recently, Chini and colleagues showed that NAD+ metabolism is essential for pancreatic 
cancer cell survival. Inhibition of NAD+ synthesis via the NAM phosphoribosyl 
transferase  pathway using FK866, resulted in reduction of NAD+ levels, glycolytic flux, lactate 
production, mitochondrial function, and pancreatic tumor growth (369).  It has been shown that 
NAD+ intracellular shortage inhibits the mTOR signaling pathway, which is the master regulator 
of macromolecule synthesis (370).  Future studies can be undertaken to test the combination 
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effect of ascorbate and mTOR inhibitor on pancreatic cancer cell survival, migration and 
invasion in vitro and in vivo.  
Cancer cell metastasis is a complex and multifaceted process (371). Spatiotemporal 
reorganization of the cytoskeleton has been shown to play an important role in cell invasion and 
metastasis (372). In this dissertation we showed that ascorbate stabilized microtubules by 
promoting α-tubulin acetylation. Microtubule dynamics contribute to actin cytoskeleton 
regulation. It has been shown that microtubule depolymerizing agents stimulated actin 
polymerization in Swiss 3T3 and Rat-2 fibroblasts. However, the microtubule-stabilizing agent 
taxol inhibited actin polymerization induced by microtubule-disrupting agents (373). Therefore, 
it is more likely that ascorbate mediated tubulin stabilization might influence actin 
polymerization, which needs to be further investigated. 
In chapter 5, novel derivatives of currently available EMT inhibitors (SAHA, MS-275) were 
evaluated for their biological activity. Of the 28 derivatives tested, St-1 and St-3 showed potent 
cytotoxicity against two pancreatic cancer cell lines possessing different genetic alterations. 
Moreover, St-1, St-3 as well as the parent compounds did not induce any cytotoxic effects on 
non-cancerous epithelial cells. St-1and St-3 showed potency in inhibiting pancreatic cancer 
CSCs.  St-1 showed similar potency to the parent compounds in inducing histone acetylation.  
Interestingly, St-3 lost the ability to inhibit HDACs, but inhibited HuR.  
Given the in vitro activities of St-1 and St-3 in inhibiting pancreatic cancer cell proliferation, 
metastasis and CSCs, a logical next step is to evaluate the anti-tumor activities of St-1 and St-3 
in vivo using a PKCY transgenic mouse model system or the PANC-1 orthotopic model system. 
Metastasis of cancer cells to liver and mechanisms of metastasis regulation by St-1 and St-3 
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needs to be investigated. CSC population in the tumors after St-1 or St-3 treatment can be 
detected by isolating CD44+CD24+EpCAM+ cells followed by the sphere formation assay.  
As St-1 exhibited similar potency in HDAC inhibition but higher potency in inhibiting cell 
growth when compared to its parent compounds (SAHA, MS-275), it might have other targets in 
addition to HDACs to execute its function. Proteomic, genetic, and bioinformatics methods can 
be employed for identification of St-1 targets. For example, a few experimental approaches 
serving this purpose are pulldown assays, drug affinity responsive target stability (DARTS), two-
dimensional (2-D) gel electrophoresis, and computational methods. Affinity based proteomics 
(pulldown) is one of the most widely applied methodology to identify the targets of biologically 
active compounds. To employ this method, St-1 has to be immobilized on a solid phase and 
exposed to a cell lysate to bind the target proteins. Proteins that bind nonspecifically to St-1 and 
matrix are removed by stringent washing prior to release of the bound protein by means of 
elution. Alternatively, biotin labelled St-1 incubated with cell lysates followed by pulldown of 
biotin-St-1-protein complex using streptavidin conjugated agarose beads can be used for St-1 
target identification. Target proteins were typically validated by tryptic digestion followed by 
mass spectrometry. Hit validation can be performed using in vitro or in silico (molecular 
docking) assays. New technologies such as DARTS, can be used to discover the direct binding 
targets of small molecules such as St-1 on a proteome scale (374). DARTS uses label free 
compounds for target identification which is one of the major advantages of this method. The 
basic principle is that target protein bound to a small molecule might be less susceptible to 
proteolysis due to local or global stabilization. Two-dimensional (2-D) gel electrophoresis can 
also be used to identify targets of small bioactive molecules like St-1, if assumption can be made 
that St-1  covalently attaches  to the target protein (375). Computational methods can be used for 
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target identification. For example, the statistics-based similarity ensemble approach compares 
protein targets considering similarities among their ligands (376). The limitations lie within the 
dependency of the method on known targets and their ligands. 
Nonspecific inhibition of HDAC inhibitors is one of the reasons for their toxicity. Therefore, 
future studies can also be undertaken to test the specificity of HDAC inhibition by St-1. 
For St-3, EMT and CSC regulation in the presence of and in the absence of HuR is an another 
important avenue that needs to be further investigated. Further, HuR has been shown to regulate 
expression of numerous mRNAs involved in cell proliferation, senescence, elevation of local 
angiogenesis, anti-apoptosis, and reduced immune recognition, in addition to the listed ones in 
Table 4 (1). Inhibition of HuR could influence these genes and pathways. Therefore, further 
studies need to investigate the role of St-3 in angiogenesis, cell senescence, apoptosis and 
immune response.  
Although data here suggested that HuR is the primary target of St-3, the possibility of other 
targets cannot be excluded. Especially, some studies showed that HuR knockdown did not 
induce massive cell death in pancreatic cancer cell lines (377, 378). Identification of other targets 
for St-3 is another future avenue that can be undertaken. Similar approaches to that described 
above can be employed to identify alternative targets of St-3.   
Identification of chemical compounds that preferentially kill CSCs depends on the ability to 
propagate stable, highly enriched populations of CSCs in vitro. However, such approaches are 
not feasible for the CSCs of solid tumors. For example breast CSCs are rapidly lost during in 
vitro culture (379). As EMT is highly associated with CSCs, in chapter 6 we established a HTS 
based approach to screening for novel EMT inhibitors as an alternative approach to target 
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pancreatic CSCs. A novel compound BSI was identified as a novel class of EMT inhibitors. BSI 
showed HDAC inhibitory activities, but is structurally different from the classical signature 
motifs of current HDAC inhibitors. BSI is a novel EMT inhibitor, which showed low 
cytotoxicity towards pancreatic cancer cell lines but had inhibitory effects on cell migration, 
invasion, and CSCs. To improve the efficacy of BSI, we have tested 6 commercially available 
BSI analogues. However, they failed to show better potency when compared to BSI in inducing 
cell death, inhibition of cell migration and CSCs.  
In vitro effects of BSI on cell migration and CSCs needs to be further validated in the PANC-1 
orthotopic model system. Since BSI is not cyto-toxic to PANC-1 cells, it is possible that BSI 
may not have effect on tumor growth. Therefore, future studies can be undertaken to discover the 
suitable combination chemotherapeutic agent which works synergistically or additively with 
BSI. 
Specificity of HDAC inhibition is another key feature that needs to be investigated. HDAC 
inhibition capacity of BSI might also be enhanced by modifying its chemical structure. For 
example, addition of an acetyl group to BSI has the potential to enhance its HDAC inhibition 
capacity because an acetyl group mimics the natural substrate of HDACs. This BSI derivative 
could potentially bind to the active site of HDACs and the rest of the molecule will traverse the 
tunnel of the active site to block the function of the HDACs.  




Identification of in vivo targets for BSI is also another future avenue that one can undertake. 
Similar approaches to that described for the identification of targets for compound St-1 can be 
employed to identify in vivo targets of BSI.   
An effort needs to be made to improve the cytotoxicity of BSI by preparing its analogues with 
the help of medicinal chemist. Anti-cancer activities of these new BSI analogues need to be 
further validated both in vitro and in vivo.  
Taken together, research outlined in this dissertation led to the development of novel EMT and 
CSC inhibitors such as high-dose vitamin C, BSI, St-1, and St-3. All of them effectively 
inhibited cell invasion, migration and CSCs and have therapeutic implications for pancreatic 
cancer treatment. Still, there are many mechanistic questions to be explored and many studies to 
be done. This work set a basis to develop these novel EMT inhibitors towards treatment or drug 
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